Nitrification inhibiting mixtures

Abstract

Heterocyclic alkynes useful for nitrification inhibition, mixtures of heterocyclic alkynes with other active ingredients, and methods of using heterocyclic alkynes and mixtures of heterocyclic alkynes with other active ingredients for nitrification inhibition and crop yield enhancement are described.

Description

[0001] NITRIFICATION INHIBITING MIXTURES CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application Serial No.63 / 622600 filed January 19, 2024, the complete disclosure of which is expressly incorporated by reference herein. Background Nitrogen is an essential element for plant health. In growing media (e.g., soil), bound nitrogen for plant nutrition can be present in the form of ammonium compounds or nitrates. The ammonium form of nitrogen is preferred because it is readily incorporated into plants. In contrast, nitrate nitrogen must be reduced to ammonium by the plant before it can be used – an energetically costly process. Ammonium nitrogen, having a positive charge, is tightly bound to growing media. Nitrogen in the form of nitrate is negatively charged, water soluble, not tightly bound to growing media and is readily washed out. Ammonia-oxidizing bacteria of the genera Nitrosomonas and Nitrobacter oxidize ammonium nitrogen to nitrate nitrogen via nitrite nitrogen. This process is known as nitrification. The extent of nitrification is dependent on the temperature, type of growing medium, pH, moisture content and biological activity. The nitrification process leads to ammonium nitrogen loss and nitrate nitrogen creation. As much as half of applied nitrogen fertilizer is lost within a year, and an undesirable concentration of nitrate in the groundwater is promoted by this process. Therefore, the inhibition of nitrification is particularly important, and is generally considered to consist in selective inhibition of the growth of the above-mentioned bacteria strains. The incorporation of certain chemical compounds in critical quantities into growing media are known to have a pronounced effect on nitrification – the conversion of reduced nitrogen such as ammonia or ammonium ions into higher oxidized forms, particularly into the nitrate form. Prevention of such nitrification in growing media is known to be beneficial and desirable from the economic and agronomic points of view since it enhances plant health, enhances crop yields, and lessens nitrate runoff. A number of nitrification inhibitors are known including linoleic acid, a-linoleic acid, methyl-p- coumarate, methyl ferulate, MHPP, Karanjin, brachialacton, 2-chloro-6-trichloromethylpyridine (nitrapyrin), dicyandiamide, 3,4-dimethylpyrazole phosphate, 4-amino-1,2,4-triazole hydrochloride, 1-amido-2-thiourea, 2-amino-4-chloro-6-methylpyrimidine, 5-ethoxy-3- trichloromethyl-1,2,4-thiodiazole, 2-sulfanilamidethiazole, 3,5-dimethyltetrahydro-1,3,5- thiadiazine-2-thione (dazomet). Nitrification inhibition has been disclosed in the following publications: US 3,494,757 and US 3,635,690, German Laid Open Application DOS 2,745,833 and GB 1,592,516. See also U.S. 3,050,380 Goring; GB 970,663 Watkins; US 3,533,774 Nault; US 4,673,429 Rieber, et al; US 4,925,476 Wagner et al; US 2015 / 0052960 Makin et al; US 2017 / 0036969 Nave et al; US 2020 / 0352162 Cunningham et al; WO 2015 / 158853 Nave et al; WO 2020 / 002472 Cunningham et al; WO 2020 / 020765 Nesvadba et al; WO 2020 / 020777 Nesvadba et al. These references and other references cited in this application, the disclosures of which are hereby incorporated herein by reference in their entirety. Some conventional nitrification inhibitors lack traits that are beneficial to their users. For example, dazomet is known to have a very non-specific action and attack non-target bacteria in growing media, especially in soil. A need still exists for nitrification inhibitors which exhibit nitrification inhibition while lacking less beneficial traits. Summary It has been found that certain alkynyl-heterocycles are useful in controlling nitrification. Specifically, certain ethynyl-thiazoles, ethynyl-oxazoles, and ethynyl-isoxazoles have been found to inhibit nitrification. Such inhibition is useful because it promotes more efficient nitrogen uptake by plants – enhancing crop yields. Nitrification inhibition is also useful for lowering the production of nitrate in growing media – particularly in soil – thereby reducing the amount unwanted nitrate in groundwater. Methods of employing the compounds include applying to and / or incorporating into growing media (e.g., soil) an effective amount of nitrification-inhibiting alkynyl heterocycle. Preferred compounds include an ethynyl-thiazole, an ethynyl-oxazole, an ethynyl-isoxazole, or mixtures thereof. Detailed Description As used herein growing medium and growing media are defined as materials in which plants grow. Exemplary growing media include, but are not limited to, soil, perlite, pumice, vermiculite, zeolite, compost, peat moss, coconut coir, sand, silt, clay, water, bark, sawdust, water, and limestone. Exemplary growing media may be outdoor-soil-based or hydroponic. As used herein alkyl refers to a C1– C6branched or unbranched group consisting of carbon and hydrogen atoms. Alkyl groups include for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i- butyl, s-butyl, t-butyl and the like. As used herein alkoxy refers to a O-C1– C6group where the oxygen atom is connected to a C1– C6branched or unbranched alkyl group. Alkoxy groups include for example methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like. As used herein thioalkyl refers to a S-C1– C6group, branched or unbranched, where the sulfur atom is connected to a C1– C6alkyl group. Thioalkyl groups include for example thiomethyl, thioethyl, thiopropyl, thioisopropyl, thiobutyl, thioisobutyl, thiosecbutyl, thiotertbutyl, and the like. As used herein cycloalkyl refers to a C3– C6group where the carbon atoms form a carbocyclic ring. Cycloalkyl groups include for example cyclopropane, cyclobutane, cyclopentane, cyclohexane and the like. As used herein alkenyl refers to a C2– C6to a branched or unbranched group consisting of carbon and hydrogen atoms and having one or more double bonds between carbon atoms. Alkenyl groups include for example ethylene, propene, 1-butene, 2-butene, isobutene and the like. As used herein cycloalkenyl refers to a C3– C6where the carbon atoms form a carbocyclic ring and contain one or two double bonds. Cycloalkenyl groups include for example cyclopropene, cyclobutene, cyclopentene, cyclohexene, cyclopentadiene, 1,4-cyclohexadiene and the like. As used herein halo refers to halogen atoms such as F, Cl, Br, and I. As used herein haloalkyl refers to a C1– C6branched or unbranched alkyl group where one or more hydrogen atoms has been replaced with a halogen atom. Haloalkyl groups include for example fluoromethyl, difluoromethyl, trifluoromethyl, chloroethyl, bromoethyl, iodobutyl, dichloroethyl, and the like. As used herein haloalkoxy refers to a C1– C6group where the oxygen atom is connected to a C1– C6branched or unbranched alkyl group where one or more hydrogen atoms has been replaced with a halogen atom. Halolkoxy groups include for example trifluoromethoxy, difluoroethoxy, chloropropoxy, bromo-iso-propoxy, dibromobutoxy, and the like. As used herein haloalkenyl refers to a C2– C6to a branched or unbranched group consisting of carbon and hydrogen atoms where one or more hydrogen atoms has been replaced with a halogen atom and having one or more double bonds between carbon atoms. Haloalkenyl groups include for example 1-chloroethylene, 3,3-difluoropropene, 4-bromo-1-butene, and the like. The term N-oxide includes any compound which has at least one tertiary nitrogen atom that is oxidized to an N-oxide moiety. N-oxides may be formed for example through oxidation of tertiary amines, such as pyridine, by hydrogen peroxide. As used herein salts and agriculturally acceptable salts include hydrofluorides, hydrochlorides, hydrobromides, hydroiodides, nitrates, hydrogensulfates, sulfates, dihydrogenphosphates, hydrogenphosphates, phosphates, carbonates, bicarbonates, oxalates, and C1– C6branched or unbranched alkanoates – such as formates, acetates, n-propionates, i-propionates, and the like. As used herein carrier includes a liquid or solid carrier. In some aspects, a carrier may include an organic or inorganic carrier. Exemplary liquid carriers include, but are not limited to: water; petroleum fractions or hydrocarbons, such as mineral oil, aromatic solvents, paraffinic oils, and the like; vegetable oils, such as soybean oil, rapeseed oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cottonseed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; esters of the above vegetable oils; esters of monoalcohols or dihydric, trihydric, or other lower polyalcohols (4-6 hydroxy containing), such as 2-ethyl hexyl stearate, n- butyl oleate, isopropyl myristate, propylene glycol dioleate, di-octyl succinate, di-butyl adipate, di-octyl phthalate and the like; esters of mono, di and polycarboxylic acids and the like; toluene; xylene; petroleum naphtha; crop oil; acetone; methyl ethyl ketone; cyclohexanone; trichloroethylene; perchloroethylene; ethyl acetate; amyl acetate; butyl acetate; propylene glycol monomethyl ether and diethylene glycol monomethyl ether; methyl alcohol; ethyl alcohol; isopropyl alcohol; amyl alcohol; ethylene glycol; propylene glycol; glycerine; N-methyl-2- pyrrolidinone; N;N-dimethyl alkylamides; dimethyl sulfoxide; and liquid fertilizers, as well as mixtures thereof. Exemplary solid carriers include, but are not limited to: silicas, silica gels, silicates, talc, kaolin, limestone, lime, chalk, bole, loess, clay, dolomite, diatomaceous earth, calcium sulfate, magnesium sulfate, magnesium oxide, ground synthetic materials, pyrophyllite clay, attapulgus clay, kieselguhr, calcium carbonate, bentonite clay, Fuller's earth, cottonseed hulls, wheat flour, soybean flour, pumice, wood flour, walnut shell flour, lignin, ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas, cereal meal, tree bark meal, wood meal, nutshell meal, cellulose powders, and mixtures thereof. Fertilizers, including but limited to, fertilizers comprising ammonia may be used as carriers. Exemplary fertilizers comprise, but are not limited to, anhydrous ammonium, ammonium salts such as ammonium nitrate, calcium ammonium nitrate, ammonium sulfate nitrate, ammonium sulfate or ammonium phosphate; organic ammonia sources, such as manure, biogas, worm castings, compost, seaweed or guano; urea-containing fertilizers such as, urea, formaldehyde urea, urea ammonium nitrate solution, urea sulfur, urea ammonium sulfate, or other urea-based fertilizers. As used herein surfactant or surfactants (e.g., wetting agents, tackifiers, dispersants, emulsifiers) include, but are not limited to: the alkali metal salts, alkaline earth metal salts and ammonium salts of fatty acids or of aromatic sulfonic acids (e.g., lignosulfonic acids, phenolsulfonic acids, naphthalenesulfonic acids, and dibutylnaphthalenesulfonic acid); alkyl- and alkylarylsulfonates; alkyl sulfates, lauryl ether sulfates and fatty alcohol sulfates; salts of sulfated hexa-, hepta- and octadecanols; salts of fatty alcohol glycol ethers; condensates of sulfonated naphthalene and its derivatives with formaldehyde; condensates of naphthalene or of the naphthalene sulfonic acids with phenol and formaldehyde; polyoxyethylene octylphenol ether; ethoxylated isooctyl-, octyl- or nonylphenol, alkylphenyl or tributylphenyl polyglycol ether; alkyl aryl polyether alcohols; isotridecyl alcohol; fatty alcohol / ethylene oxide condensates; ethoxylated castor oil; polyoxyethylene alkyl ethers or polyoxypropylene alkyl ethers; lauryl alcohol polyglycol ether acetate; sorbitol esters; lignosulfite waste liquors and proteins; denatured proteins, polysaccharides (e.g., methylcellulose); hydrophobically modified starches; and polyvinyl alcohol, polycarboxylates, polyalkoxylates, polyvinyl amine, polyethyleneimine, polyvinylpyrrolidone, and copolymers thereof. As used herein stabilizer includes compounds or ingredients that enhance the stability of active ingredients by decreasing undesirable reactions of active ingredients. Stabilizers may be employed to enhance storage stability of formulated or unformulated active ingredients. For example, stabilizers may decrease undesirable oxidation, reduction, condensation, hydrolysis, addition, elimination, ionic, or free radical reactions. Exemplary stabilizers include, but are not limited to, oxygen scavengers, free radical scavengers, free radical inhibitors, ion scavengers, polymerization inhibitors, and the like. As used herein adjuvant includes agriculturally acceptable adjuvants. Exemplary agriculturally acceptable adjuvants include, but are not limited to, antifreeze agents, antifoam agents, compatibilizing agents, sequestering agents, neutralizing agents and buffers, corrosion inhibitors, colorants, odorants, penetration aids, wetting agents, spreading agents, dispersing agents, thickening agents, freeze point depressants, antimicrobial agents, crop oil (concentrates), adhesives (for instance, for use in seed treatment formulations), surfactants, protective colloids, emulsifiers, tackifiers, and mixtures thereof. Exemplary agriculturally acceptable adjuvants include, but are not limited to, crop oil concentrates (e.g., 85% mineral oil + 15% emulsifiers); nonylphenol ethoxylates; benzylcocoalkyldimethyl quaternary ammonium salts; blends of petroleum hydrocarbon, alkyl esters, organic acids, and anionic surfactants; C9-C11alkylpolyglycoside; phosphate alcohol ethoxylates; natural primary alcohol (C12-C16) ethoxylate; di-sec-butylphenol EO-PO block copolymers; polysiloxane-methyl cap; nonylphenol ethoxylate+urea ammonium nitrates; emulsified methylated seed oils; tridecyl alcohol (synthetic) ethoxylates (e.g., 8 EO); tallow amine ethoxylates (e.g., 15 EO); and PEG(400) dioleate-99. Exemplary agriculturally acceptable adjuvants include, but are not limited to, thickening agents (i.e., thickeners). Exemplary thickeners include, but are not limited to, polysaccharides (e.g., xanthan gum), organic and inorganic sheet minerals, and mixtures thereof. Exemplary agriculturally acceptable adjuvants include, but are not limited to, antifoam agents. Exemplary antifoam agents include, but are not limited to, silicone emulsions, long-chain alcohols, fatty acids, fatty acid salts, organofluorine compounds, and mixtures thereof. Exemplary agriculturally acceptable adjuvants include, but are not limited to, antifreeze agents. Exemplary antifreeze agents, include, but are not limited to ethylene glycol, propylene glycol, urea, glycerol, and mixtures thereof. Exemplary agriculturally acceptable adjuvants include, but are not limited to, colorants. Exemplary colorants include, but are not limited to, the dyes known under the names Rhodamine B, pigment blue 15:4, pigment blue 15:3, pigment blue 15:2, pigment blue 15:1, pigment blue 80, pigment yellow 1, pigment yellow 13, pigment red 112, pigment red 48:2, pigment red 48:1, pigment red 57:1, pigment red 53:1, pigment orange 43, pigment orange 34, pigment orange 5, pigment green 36, pigment green 7, pigment white 6, pigment brown 25, basic violet 10, basic violet 49, acid red 51, acid red 52, acid red 14, acid blue 9, acid yellow 23, basic red 10, basic red 108, and mixtures thereof. Exemplary agriculturally acceptable adjuvants include, but are not limited to, adhesives. Exemplary adhesives include, but are not limited to, polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol, tylose, and mixtures thereof. Compounds and compositions described herein may be formulated for use. Exemplary formulations include, but are not limited to, emulsifiable concentrates, oil dispersions, solution concentrates, suspension emulsions, micro-emulsions, granules, wettable powders, seed treatments, oil-in-water emulsions, water-dispersible granules. Such formulations are described in Chemistry and Technology of Agrochemical Formulations, D.A. Knowles Ed., Kluwer Academic Publishers, 2012. As used herein an agriculturally effective amount of nitrification inhibiting compound is an amount of compound that produces a measurable effect on one or more of: ammonium nitrogen, nitrification inhibition, nitrate formation, increased plant health, increased plant growth, increased plant or crop yield, bacteria of the genera Nitrosomonas and Nitrobacter. In general, an agriculturally effective amount of an active ingredient is from about 0.0001 grams per hectare to about 5000 grams per hectare, preferably from about 0.0001 grams per hectare to about 500 grams per hectare, and it is even more preferably from about 0.0001 grams per hectare to about 50 grams per hectare. Active ingredients include, but are not limited to, nitrification- inhibiting compounds described herein, as well as active ingredients of group AIG-1, defined below. As used herein “compound” or “compounds” comprise chemicals defined by molecular structure formulas and / or chemical names as well as their tautomers, salts, N-oxides, and stereoisomers. As used herein the term “locus” means a habitat, breeding ground, plant, seed, soil, material, or environment, in which a pest is growing, may grow, or may traverse. For example, a locus may be: where crops, trees, fruits, cereals, fodder species, vines, turf, and / or ornamental plants, are growing; where domesticated animals are residing; the interior or exterior surfaces of buildings (such as places where grains are stored); the materials of construction used in buildings (such as impregnated wood); and the soil around buildings. Examples provided herein are not exhaustive and should not be construed as limiting. It is understood that a substituent should comply with chemical bonding rules and steric compatibility constraints in relation to the particular molecule to which it is attached. These definitions are only to be used for the purposes of this disclosure. The term “Actives” or “Active ingredient” includes the compounds listed in the paragraph immediately below, each of which is considered as “active’ or an “active ingredient” These common names may be found in several locations, such as, the British Crop Production Council’s “Compendium of Pesticide Common Names” located at https: / / pesticidecompendium.bcpc.org / . These active ingredients may be used in mixtures with the molecules disclosed below for a variety of reasons. The term “Active Ingredient Group One” or “AIG-1” means the following preferred group of mixture partners that perform multiple agricultural functions selected from the group consisting of 2,4-D, abamectin, acephate, acequinocyl, acetamiprid, acetoprole, acibenzolar, acrinathrin, acynonapyr, afidopyropen, alanycarb, aldicarb, aldimorph, allethrin, alpha-bromadiolone, alpha- cypermethrin, alpha-endosulfan, ametoctradin, amicarbazone, amidoflumet, amidosulfuron, aminocyclopyrachlor, aminopyralid, aminopyrifen, amisulbrom, amitraz, anisiflupurin, aviglycine, azadirachtin, azafenidin, azamethiphos, azimsulfuron, azinphos-ethyl, azinphos- methyl, azocyclotin, azoxystrobin, beflubutamid, beflubutamid-M, benalaxyl-M, bencarbazone, benclothiaz, bendiocarb, benfuracarb, benquitrione, bensultap, benthiavalicarb, benzfendizone, benzobicyclon, benzovindiflupyr, benzoximate, benzpyrimoxan, beta-cyfluthrin, beta- cypermethrin, bethoxazin, bicyclopyrone, bifenazate, bifenthrin, bioallethrin, bioresmethrin, bipyrazone, bispyribac, bistrifluron, bisulflufen, bixafen, bixlozone, boscalid, broclozone, broflanilide, bromopropylate, bromuconazole, buprofezin, butafenacil, butocarboxim, butoxycarboxim, butroxydim, cadusafos, cafenstrole, carbaryl, carbofuran, carbosulfan, carboxin, carfentrazone, carpropamid, cartap hydrochloride, carvone, chinomethionat, chlorantraniliprole, chlordane, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroinconazide, chloroprallethrin, chlorpyrifos, chlorpyrifos-methyl, cholecalciferol, chromafenozide, cinidon-ethyl, clacyfos, clethodim, clodinafop, clofencet, clofentezine, clopyralid, cloquintocet, cloransulam, clothianidin, copper hydroxide, coumaphos, coumoxystrobin, cumyluron, cyanophos, cyantraniliprole, cyazofamid, cybutryne, cyclanilide, cyclaniliprole, cyclobutrifluram, cycloprothrin, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxaprid, cyenopyrafen, cyetpyrafen, cyflufenamid, cyflumetofen, cyfluthrin, cyhalodiamide, cyhalofop, cyhalothrin, cyhexatin, cymoxanil, cypermethrin, cyphenothrin, cyprodinil, cyproflanilide, cyprosulfamide, cypyrafluone, cyromazine, d-cis-trans allethrin, DDVP, debacarb, deltamethrin, demeton-S-methyl, diafenthiuron, diazinon, dichlobentiazox, dichlorprop-P, dichlorvos, diclocymet, dicloromezotiaz, diclosulam, dicofol, dicrotophos, dicyclanil, dicyclonon, difenoconazole, diflovidazin, diflubenzuron, diflufenzopyr, diflumetorim, dimefluthrin, dimepropyridaz, dimesulfazet, dimethenamid, dimethenamid-P, dimethoate, dimethylvinphos, dimoxystrobin, dimpropyridaz, diniconazole-M, dinotefuran, diofenolan, dioxopyritrione, dipymetitrone, disulfoton, DNOC, d-trans allethrin, emamectin, emamectin benzoate, empenthrin, endosulfan, enoxastrobin, EPN, epocholeone, epoxiconazole, epsilon- metofluthrin, epsilon-momfluorothrin, epyrifenacil, ergocalciferol, esfenvalerate, ethaboxam, ethametsulfuron, ethiofencarb, ethion, ethiprole, ethoprophos, ethoxysulfuron, etobenzanid, etofenprox, etoxazole, famoxadone, famphur, fenamidone, fenaminstrobin, fenamiphos, fenazaquin, fenbuconazole, fenbutatin oxide, fenhexamid, fenitrothion, fenmezoditiaz, fenobucarb, fenoxanil, fenoxasulfone, fenoxycarb, fenpicoxamid, fenpropathrin, fenpyrazamine, fenpyrazone, fenpyroximate, fenquinotrione, fenthion, fentrazamide, fenvalerate, feproxydim, fipronil, flazasulfuron, flometoquin, flonicamid, florasulam, florpyrauxifen, florylpicoxamid, fluacrypyrim, fluazaindolizine, fluazolate, fluazuron, flubendiamide, flubeneteram, flucarbazone, flucetosulfuron, fluchloraminopyr, fluchlordiniliprole, flucycloxuron, flucythrinate, fludioxonil, fluensulfone, flufenacet, flufenerim, flufenoxadiazam, flufenoximacil, flufenoxuron, flufenoxystrobin, flufenprox, flufenpyr, flufiprole, fluhexafon, fluindapyr, flumethrin, flumetover, flumetsulam, flumetylsulforim, flumiclorac, flumioxazin, flumipropyn, flumorph, fluopicolide, fluopimomide, fluopyram, fluoxapiprolin, fluoxastrobin, fluoxytioconazole, flupentiofenox, flupoxam, flupropacil, flupyradifurone, flupyrimin, flupyroxystrobin, flupyrsulfuron, fluquinconazole, fluroxypyr, flusulfinam, fluthiacet, flutianil, fluxametamide, fluxapyroxad, foramsulfuron, formetanate, fosthiazate, furametpyr, furathiocarb, furilazole, gamma-cyhalothrin, glufosinate-P, glyphosate, halauxifen, halfenprox, halofenozide, halosulfuron, heptafluthrin, heptenophos, hexaflumuron, hexythiazox, hydramethylnon, hydroprene, icafolin, imazamox, imazapic, imazapyr, imazosulfuron, imicyafos, imidacloprid, imiprothrin, indanofan, indazapyroxamet, indaziflam, indolauxipyr, indoxacarb, inpyrfluxam, iodosulfuron, iofensulfuron, ipconazole, ipfencarbazone, ipfentrifluconazole, ipflufenoquin, iprovalicarb, iptriazopyrid, isocycloseram, isofenphos, isofetamid, isoflualanam, isoflucypram, isoprocarb, isopyrazam, isotianil, isoxachlortole, isoxadifen, isoxaflutole, isoxathion, kadethrin, kappa-bifenthrin, kappa-tefluthrin, karetazan, kinoprene, kresoxim-methyl, lambda-cyhalothrin, lancotrione, ledprona, lepimectin, lufenuron, malathion, mancozeb, mandestrobin, mandipropamid, MCPA, mecarbam, mefenoxam, mefenpyr, mefentrifluconazole, meperfluthrin, mepronil, meptyldinocap, mesosulfuron, mesotrione, metaflumizone, metalaxyl, metalaxyl-M, metamifop, metarylpicoxamid, metazosulfuron, metcamifen, metconazole, methamidophos, methenamine, methidathion, methiocarb, methiozolin (cancelled), methomyl, methoprene, methoxychlor, methoxyfenozide, methylneodecanamide, metobenzuron, metofluthrin, metolcarb, metominostrobin, metosulam, metproxybicyclone, metrafenone, metsulfuron, metyltetraprole, mevinphos, milbemectin, mivorilaner, modoflaner, momfluorothrin, monocrotophos, myclobutanil, naled, napropamide-M, nicobifen, nicofluprole, nicosulfuron, nitenpyram, nithiazine, nitrapyrin, novaluron, noviflumuron, omethoate, orthosulfamuron, orysastrobin, oxadiargyl, oxamyl, oxasulfuron, oxathiapiprolin, oxaziclomefone, oxazosulfyl, oxpoconazole, oxydemeton-methyl, parathion, parathion-methyl, penflufen, penoxsulam, penthiopyrad, pentoxazone, permethrin, pethoxamid, phenothrin, phenthoate, phorate, phosalone, phosmet, phosphamidon, phosphocarb, phoxim, picarbutrazox, picloram, picolinafen, picoxystrobin, pinoxaden, pioxaniliprole, piperflanilide, pirimicarb, pirimiphos-methyl, polyoxorim, prallethrin, profenofos, profluazol, profluthrin, profoxydim, prohydrojasmon, pronitridine, propargite, propetamphos, propiconazole, propoxur, propoxycarbazone, propyrisulfuron, propyzamide, proquinazid, prosulfuron, prothioconazole, prothiofos, protrifenbute, pydiflumetofen, pyflubumide, pymetrozine, pyraclofos, pyraclonil, pyraclostrobin, pyraflufen, pyrafluprole, pyrametostrobin, pyraoxystrobin, pyrapropoyne, pyraquinate, pyrasulfotole, pyraziflumid, pyrethrum, pyribencarb, pyribenzoxim, pyridaben, pyridachlometyl, pyridafol, pyridalyl, pyridaphenthion, pyriflubenzoxim, pyrifluquinazon, pyriftalid, pyrimethanil, pyrimidifen, pyriminobac, pyriminostrobin, pyrimisulfan, pyriofenone, pyriprole, pyriproxyfen, pyrisoxazole, pyrithiobac, pyroxasulfone, pyroxsulam, quinalphos, quinofumelin, quinoxyfen, quizalofop-P, rescalure, resmethrin, rimisoxafen, rimsulfuron, rotenone, saflufenacil, seboctylamine, sedaxane, silafluofen, silthiofam, simeconazole, sintofen, S-metolachlor, spidoxamat, spiflumetofen, spinetoram, spinosad, spirobudifen, spirodiclofen, spiromesifen, spiropidion, spirotetramat, spiroxamine, sulcotrione, sulfentrazone, sulfiflumin, sulfluramid, sulfosulfuron, sulfotep, sulfoxaflor, tau-fluvalinate, tebuconazole, tebufenozide, tebufenpyrad, tebufloquin, tebupirimfos, teflubenzuron, tefluthrin, tefuryltrione, tembotrione, temephos, tepraloxydim, terbufos, tetflupyrolimet, tetrachlorantraniliprole, tetrachlorvinphos, tetradifon, tetramethrin, tetramethylfluthrin, tetraniliprole, thenylchlor, theta-cypermethrin, thiabendazole, thiacloprid, thiamethoxam, thiazopyr, thidiazimin, thiencarbazone, thifluzamide, thiocyclam, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-sodium, thiram, tiadinil, tiafenacil, tigolaner, tiorantraniliprole, tioxazafen, tolfenpyrad, tolprocarb, tolpyralate, topramezone, tralkoxydim, tralomethrin, tralopyril, transfluthrin, triafamone, triazamate, triaziflam, triazophos, tribufos, trichlorfon, triclopyr, triclopyricarb, trifloxystrobin, trifloxysulfuron, trifludimoxazin, trifluenfuronate, triflumezopyrim, triflumuron, triflusulfuron, trimethacarb, trinexapac, tripyrasulfone, triticonazole, tritosulfuron, tyclopyrazoflor, umifoxolaner, uniconazole-P, valifenalate, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, and zoxamide. The terms “Active Ingredient Group Two” or “AIG-2” and the term “Active ingredient Group Three” or “AIG-3” refer to groups of nitrification inhibiting compounds which are described in more detail below. Compounds described herein are nitrification inhibitors. One or more compounds described herein may be incorporated into a composition comprising other ingredients such as one or more compounds of AIG-1, carriers, surfactants, and adjuvants. A composition optionally may include a source of ammonia. To enhance plant health and / or improve crop yields, a compound or composition may be applied to a growing medium with or without a source of ammonia. Sources of ammonia include anhydrous ammonia, urea, urea-ammonium nitrate, and manure. A compound or composition may be mixed directly with the ammonia source. A mixture of compound or composition and ammonia source may be applied directly to a growing medium, such as soil. A compound or composition and the ammonia source may be applied separately to the growing medium, such as soil. A compound or composition and the ammonia source may be applied separately and simultaneously. A compound or composition and the ammonia source may be applied separately and sequentially. Sequential application of a compound or composition and a source of ammonia may take place within 24 hours, within 1 to 3 days, within 1 to 5 days, within one week, within two weeks, within three weeks, or within four weeks; between one week and two weeks, between one week and three weeks, or between one week and four weeks; between two weeks and three weeks, or between two weeks and four weeks. A compound or composition may be applied before planting or after planting. A compound or composition may be applied pre- emergence or post-emergence. In certain aspects a nitrification inhibiting composition or method provided herein comprises one or more of the following compounds and agriculturally acceptable salts, tautomers, stereoisomers, and N-oxides thereof: R1R1R1 where R1-R4are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R1– R4is C≡C or C≡C-TMS. R1R1R1R N 4 where R1– R4are independently H, C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R1– R4is C≡C or C≡C-TMS. NN R14Formula IV, where - H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R11– R14is C≡C or C≡C-TMS. NN R14 R11and R14are independently C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R11and R14is C≡C or C≡C-TMS. R12– R13are H. R23R22R24Formula V, where H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R21– R24is C≡C or C≡C-TMS. R23Formula Va, where are independently C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R21and R24is C≡C or C≡C-TMS. R22, R23, and R25are H. R32Formula VI, where R31– R34are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R31– R34is C≡C or C≡C-TMS. R32R N33Formula VIa, where independently C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R31and R33is C≡C or C≡C-TMS. R32, and R34are H. R42N R43 trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R41– R44is C≡C or C≡C-TMS. R42N R43Formula VIIa, where R41and R43are independently C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R41and R43is C≡C or C≡C-TMS. R42and R44are H.S NR53Formula VIII, where are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R51, R52, or R53is C≡C or C≡C-TMS. SNR53Formula VIIIa, where are independently H, C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R51, R52, or R53is C≡C or C≡C-TMS. ONR63Formula IX, where are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R61, R62, or R63is C≡C or C≡C-TMS.O NR63Formula IXa, where are independently H, C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R61, R62, or R63is C≡C or C≡C-TMS. R71N Formula X, where and R74are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, wherein at least one of R71, R72, R73, or R74is C≡C or C≡C-TMS. R71Formula Xa, where R74are independently H, C≡C, C≡C-TMS, C≡CMe, OEt, OMe, OCF3, OH, I, Cl, F, methyl, ethyl, cyclopropyl, propyl, SMe, CN, benzyl, acetyl, vinyl, wherein at least one of R71, R72, R73, or R74is C≡C or C≡C-TMS. In certain aspects a nitrification inhibiting compound, composition, or method provided herein comprises a compound selected from the group (AIG-2) consisting ofN O N O,,

[0002] ,In certain aspects a nitrification inhibiting compound, composition, or method provided herein comprises a compound selected from the group (AIG-3) consisting of SN O N O, and agriculturally acceptable salts, N-oxides, stereoisomers, and tautomers thereof. In certain aspects a nitrification inhibiting compound is selected from the group consisting of compounds in Table 1, and agriculturally acceptable salts, N-oxides, stereoisomers, and tautomers thereof. A nitrification composition may be mixed with active ingredients and other mixture partners to enhance the usefulness of the composition. Such active ingredients may have, for example, acaricidal, insecticidal, fungicidal, herbicidal, nematicidal activity, as well as other materials, compounds, and compositions. In light of the above, the following details are additionally provided. 1. A composition comprising a compound of Formula I combined with a mixture partner selected from AIG-1. 2. A composition comprising a compound of Formula Ia combined with a mixture partner selected from AIG-1. 3. A composition comprising a compound of Formula II combined with a mixture partner selected from AIG-1. 4. A composition comprising a compound of Formula IIa combined with a mixture partner selected from AIG-1. 5. A composition comprising a compound of Formula III combined with a mixture partner selected from AIG-1. 6. A composition comprising a compound of Formula IIIa combined with a mixture partner selected from AIG-1. 7. A composition comprising a compound of Formula IV combined with a mixture partner selected from AIG-1. 8. A composition comprising a compound of Formula IVa combined with a mixture partner selected from AIG-1. 9. A composition comprising a compound of Formula V combined with a mixture partner selected from AIG-1. 10. A composition comprising a compound of Formula Va combined with a mixture partner selected from AIG-1. 11. A composition comprising a compound of Formula VI combined with a mixture partner selected from AIG-1. 12. A composition comprising a compound of Formula VIa combined with a mixture partner selected from AIG-1. 13. A composition comprising a compound of Formula VII combined with a mixture partner selected from AIG-1. 14. A composition comprising a compound of Formula VIIa combined with a mixture partner selected from AIG-1. 15. A composition comprising a compound of Formula VIII combined with a mixture partner selected from AIG-1. 16. A composition comprising a compound of Formula VIIIa combined with a mixture partner selected from AIG-1. 17. A composition comprising a compound of Formula IX combined with a mixture partner selected from AIG-1. 18. A composition comprising a compound of Formula IXa combined with a mixture partner selected from AIG-1. 19. A composition comprising a compound of Formula X combined with a mixture partner selected from AIG-1. 20. A composition comprising a compound of Formula Xa combined with a mixture partner selected from AIG-1. 21. A composition comprising one or more active ingredients selected from AIG-2 combined with a mixture partner selected from AIG-1. 22. A composition comprising one or more active ingredients selected from AIG-3 combined with a mixture partner selected from AIG-1. 23. A composition comprising AIG-3.1 combined with a mixture partner selected from AIG-1. 24. A composition comprising AIG-3.2 combined with a mixture partner selected from AIG-1. 25. A composition comprising AIG-3.3 combined with a mixture partner selected from AIG-1. 26. A composition comprising AIG-3.4 combined with a mixture partner selected from AIG-1. 27. A composition comprising AIG-3.5 combined with a mixture partner selected from AIG-1. 28. A composition having a compound selected from AIG-3 combined with mixture partner 2,4- D. 28. A composition having a compound selected from AIG-3 combined with mixture partner abamectin. 30. A composition having a compound selected from AIG-3 combined with mixture partner acephate. 31. A composition having a compound selected from AIG-3 combined with mixture partner acequinocyl. 32. A composition having a compound selected from AIG-3 combined with mixture partner acetamiprid. 33. A composition having a compound selected from AIG-3 combined with mixture partner acetoprole. 34. A composition having a compound selected from AIG-3 combined with mixture partner acibenzolar. 35. A composition having a compound selected from AIG-3 combined with mixture partner acrinathrin. 36. A composition having a compound selected from AIG-3 combined with mixture partner acynonapyr. 37. A composition having a compound selected from AIG-3 combined with mixture partner afidopyropen. 38. A composition having a compound selected from AIG-3 combined with mixture partner alanycarb. 39. A composition having a compound selected from AIG-3 combined with mixture partner aldicarb. 40. A composition having a compound selected from AIG-3 combined with mixture partner aldimorph. 41. A composition having a compound selected from AIG-3 combined with mixture partner allethrin. 42. A composition having a compound selected from AIG-3 combined with mixture partner alpha-bromadiolone. 43. A composition having a compound selected from AIG-3 combined with mixture partner alpha-cypermethrin. 44. A composition having a compound selected from AIG-3 combined with mixture partner alpha-endosulfan. 45. A composition having a compound selected from AIG-3 combined with mixture partner ametoctradin. 46. A composition having a compound selected from AIG-3 combined with mixture partner amicarbazone. 47. A composition having a compound selected from AIG-3 combined with mixture partner amidoflumet. 48. A composition having a compound selected from AIG-3 combined with mixture partner amidosulfuron. 49. A composition having a compound selected from AIG-3 combined with mixture partner aminocyclopyrachlor. 50. A composition having a compound selected from AIG-3 combined with mixture partner aminopyralid. 51. A composition having a compound selected from AIG-3 combined with mixture partner aminopyrifen. 52. A composition having a compound selected from AIG-3 combined with mixture partner amisulbrom. 53. A composition having a compound selected from AIG-3 combined with mixture partner amitraz. 54. A composition having a compound selected from AIG-3 combined with mixture partner anisiflupurin. 55. A composition having a compound selected from AIG-3 combined with mixture partner aviglycine. 56. A composition having a compound selected from AIG-3 combined with mixture partner azadirachtin. 57. A composition having a compound selected from AIG-3 combined with mixture partner azafenidin. 58. A composition having a compound selected from AIG-3 combined with mixture partner azamethiphos. 59. A composition having a compound selected from AIG-3 combined with mixture partner azimsulfuron. 60. A composition having a compound selected from AIG-3 combined with mixture partner azinphos-ethyl. 61. A composition having a compound selected from AIG-3 combined with mixture partner azinphos-methyl. 62. A composition having a compound selected from AIG-3 combined with mixture partner azocyclotin. 63. A composition having a compound selected from AIG-3 combined with mixture partner azoxystrobin. 64. A composition having a compound selected from AIG-3 combined with mixture partner beflubutamid. 65. A composition having a compound selected from AIG-3 combined with mixture partner beflubutamid-M. 66. A composition having a compound selected from AIG-3 combined with mixture partner benalaxyl-M. 67. A composition having a compound selected from AIG-3 combined with mixture partner bencarbazone. 68. A composition having a compound selected from AIG-3 combined with mixture partner benclothiaz. 69. A composition having a compound selected from AIG-3 combined with mixture partner bendiocarb. 70. A composition having a compound selected from AIG-3 combined with mixture partner benfuracarb. 71. A composition having a compound selected from AIG-3 combined with mixture partner benquitrione. 72. A composition having a compound selected from AIG-3 combined with mixture partner bensultap. 73. A composition having a compound selected from AIG-3 combined with mixture partner benthiavalicarb. 74. A composition having a compound selected from AIG-3 combined with mixture partner benzfendizone. 75. A composition having a compound selected from AIG-3 combined with mixture partner benzobicyclon. 76. A composition having a compound selected from AIG-3 combined with mixture partner benzovindiflupyr. 77. A composition having a compound selected from AIG-3 combined with mixture partner benzoximate. 78. A composition having a compound selected from AIG-3 combined with mixture partner benzpyrimoxan. 79. A composition having a compound selected from AIG-3 combined with mixture partner beta-cyfluthrin. 80. A composition having a compound selected from AIG-3 combined with mixture partner beta-cypermethrin. 81. A composition having a compound selected from AIG-3 combined with mixture partner bethoxazin. 82. A composition having a compound selected from AIG-3 combined with mixture partner bicyclopyrone. 83. A composition having a compound selected from AIG-3 combined with mixture partner bifenazate. 84. A composition having a compound selected from AIG-3 combined with mixture partner bifenthrin. 85. A composition having a compound selected from AIG-3 combined with mixture partner bioallethrin. 86. A composition having a compound selected from AIG-3 combined with mixture partner bioresmethrin. 87. A composition having a compound selected from AIG-3 combined with mixture partner bipyrazone. 88. A composition having a compound selected from AIG-3 combined with mixture partner bispyribac. 89. A composition having a compound selected from AIG-3 combined with mixture partner bistrifluron. 90. A composition having a compound selected from AIG-3 combined with mixture partner bisulflufen. 91. A composition having a compound selected from AIG-3 combined with mixture partner bixafen. 92. A composition having a compound selected from AIG-3 combined with mixture partner bixlozone. 93. A composition having a compound selected from AIG-3 combined with mixture partner boscalid. 94. A composition having a compound selected from AIG-3 combined with mixture partner broclozone. 95. A composition having a compound selected from AIG-3 combined with mixture partner broflanilide. 96. A composition having a compound selected from AIG-3 combined with mixture partner bromopropylate. 97. A composition having a compound selected from AIG-3 combined with mixture partner bromuconazole. 98. A composition having a compound selected from AIG-3 combined with mixture partner buprofezin. 99. A composition having a compound selected from AIG-3 combined with mixture partner butafenacil. 100. A composition having a compound selected from AIG-3 combined with mixture partner butocarboxim. 101. A composition having a compound selected from AIG-3 combined with mixture partner butoxycarboxim. 102. A composition having a compound selected from AIG-3 combined with mixture partner butroxydim. 103. A composition having a compound selected from AIG-3 combined with mixture partner cadusafos. 104. A composition having a compound selected from AIG-3 combined with mixture partner cafenstrole. 105. A composition having a compound selected from AIG-3 combined with mixture partner carbaryl. 106. A composition having a compound selected from AIG-3 combined with mixture partner carbofuran. 107. A composition having a compound selected from AIG-3 combined with mixture partner carbosulfan. 108. A composition having a compound selected from AIG-3 combined with mixture partner carboxin. 109. A composition having a compound selected from AIG-3 combined with mixture partner carfentrazone. 110. A composition having a compound selected from AIG-3 combined with mixture partner carpropamid. 111. A composition having a compound selected from AIG-3 combined with mixture partner cartap hydrochloride. 112. A composition having a compound selected from AIG-3 combined with mixture partner carvone. 113. A composition having a compound selected from AIG-3 combined with mixture partner chinomethionat. 114. A composition having a compound selected from AIG-3 combined with mixture partner chlorantraniliprole. 115. A composition having a compound selected from AIG-3 combined with mixture partner chlordane. 116. A composition having a compound selected from AIG-3 combined with mixture partner chlorethoxyfos. 117. A composition having a compound selected from AIG-3 combined with mixture partner chlorfenapyr. 118. A composition having a compound selected from AIG-3 combined with mixture partner chlorfenvinphos. 119. A composition having a compound selected from AIG-3 combined with mixture partner chlorfluazuron. 120. A composition having a compound selected from AIG-3 combined with mixture partner chlormephos. 121. A composition having a compound selected from AIG-3 combined with mixture partner chloroinconazide. 122. A composition having a compound selected from AIG-3 combined with mixture partner chloroprallethrin. 123. A composition having a compound selected from AIG-3 combined with mixture partner chlorpyrifos. 124. A composition having a compound selected from AIG-3 combined with mixture partner chlorpyrifos-methyl. 125. A composition having a compound selected from AIG-3 combined with mixture partner cholecalciferol. 126. A composition having a compound selected from AIG-3 combined with mixture partner chromafenozide. 127. A composition having a compound selected from AIG-3 combined with mixture partner cinidon-ethyl. 128. A composition having a compound selected from AIG-3 combined with mixture partner clacyfos. 129. A composition having a compound selected from AIG-3 combined with mixture partner clethodim. 130. A composition having a compound selected from AIG-3 combined with mixture partner clodinafop. 131. A composition having a compound selected from AIG-3 combined with mixture partner clofencet. 132. A composition having a compound selected from AIG-3 combined with mixture partner clofentezine. 133. A composition having a compound selected from AIG-3 combined with mixture partner clopyralid. 134. A composition having a compound selected from AIG-3 combined with mixture partner cloquintocet. 135. A composition having a compound selected from AIG-3 combined with mixture partner cloransulam. 136. A composition having a compound selected from AIG-3 combined with mixture partner clothianidin. 137. A composition having a compound selected from AIG-3 combined with mixture partner copper hydroxide. 138. A composition having a compound selected from AIG-3 combined with mixture partner coumaphos. 139. A composition having a compound selected from AIG-3 combined with mixture partner coumoxystrobin. 140. A composition having a compound selected from AIG-3 combined with mixture partner cumyluron. 141. A composition having a compound selected from AIG-3 combined with mixture partner cyanophos. 142. A composition having a compound selected from AIG-3 combined with mixture partner cyantraniliprole. 143. A composition having a compound selected from AIG-3 combined with mixture partner cyazofamid. 144. A composition having a compound selected from AIG-3 combined with mixture partner cybutryne. 145. A composition having a compound selected from AIG-3 combined with mixture partner cyclanilide. 146. A composition having a compound selected from AIG-3 combined with mixture partner cyclaniliprole. 147. A composition having a compound selected from AIG-3 combined with mixture partner cyclobutrifluram. 148. A composition having a compound selected from AIG-3 combined with mixture partner cycloprothrin. 149. A composition having a compound selected from AIG-3 combined with mixture partner cyclopyranil. 150. A composition having a compound selected from AIG-3 combined with mixture partner cyclopyrimorate. 151. A composition having a compound selected from AIG-3 combined with mixture partner cyclosulfamuron. 152. A composition having a compound selected from AIG-3 combined with mixture partner cycloxaprid. 153. A composition having a compound selected from AIG-3 combined with mixture partner cyenopyrafen. 154. A composition having a compound selected from AIG-3 combined with mixture partner cyetpyrafen. 155. A composition having a compound selected from AIG-3 combined with mixture partner cyflufenamid. 156. A composition having a compound selected from AIG-3 combined with mixture partner cyflumetofen. 157. A composition having a compound selected from AIG-3 combined with mixture partner cyfluthrin. 158. A composition having a compound selected from AIG-3 combined with mixture partner cyhalodiamide. 159. A composition having a compound selected from AIG-3 combined with mixture partner cyhalofop. 160. A composition having a compound selected from AIG-3 combined with mixture partner cyhalothrin. 161. A composition having a compound selected from AIG-3 combined with mixture partner cyhexatin. 162. A composition having a compound selected from AIG-3 combined with mixture partner cymoxanil. 163. A composition having a compound selected from AIG-3 combined with mixture partner cypermethrin. 164. A composition having a compound selected from AIG-3 combined with mixture partner cyphenothrin. 165. A composition having a compound selected from AIG-3 combined with mixture partner cyprodinil. 166. A composition having a compound selected from AIG-3 combined with mixture partner cyproflanilide. 167. A composition having a compound selected from AIG-3 combined with mixture partner cyprosulfamide. 168. A composition having a compound selected from AIG-3 combined with mixture partner cypyrafluone. 169. A composition having a compound selected from AIG-3 combined with mixture partner cyromazine. 170. A composition having a compound selected from AIG-3 combined with mixture partner d- cis-trans allethrin. 171. A composition having a compound selected from AIG-3 combined with mixture partner DDVP. 172. A composition having a compound selected from AIG-3 combined with mixture partner debacarb. 173. A composition having a compound selected from AIG-3 combined with mixture partner deltamethrin. 174. A composition having a compound selected from AIG-3 combined with mixture partner demeton-S-methyl. 175. A composition having a compound selected from AIG-3 combined with mixture partner diafenthiuron. 176. A composition having a compound selected from AIG-3 combined with mixture partner diazinon. 177. A composition having a compound selected from AIG-3 combined with mixture partner dichlobentiazox. 178. A composition having a compound selected from AIG-3 combined with mixture partner dichlorprop-P. 179. A composition having a compound selected from AIG-3 combined with mixture partner dichlorvos. 180. A composition having a compound selected from AIG-3 combined with mixture partner diclocymet. 181. A composition having a compound selected from AIG-3 combined with mixture partner dicloromezotiaz. 182. A composition having a compound selected from AIG-3 combined with mixture partner diclosulam. 183. A composition having a compound selected from AIG-3 combined with mixture partner dicofol. 184. A composition having a compound selected from AIG-3 combined with mixture partner dicrotophos. 185. A composition having a compound selected from AIG-3 combined with mixture partner dicyclanil. 186. A composition having a compound selected from AIG-3 combined with mixture partner dicyclonon. 187. A composition having a compound selected from AIG-3 combined with mixture partner difenoconazole. 188. A composition having a compound selected from AIG-3 combined with mixture partner diflovidazin. 189. A composition having a compound selected from AIG-3 combined with mixture partner diflubenzuron. 190. A composition having a compound selected from AIG-3 combined with mixture partner diflufenzopyr. 191. A composition having a compound selected from AIG-3 combined with mixture partner diflumetorim. 192. A composition having a compound selected from AIG-3 combined with mixture partner dimefluthrin. 193. A composition having a compound selected from AIG-3 combined with mixture partner dimepropyridaz. 194. A composition having a compound selected from AIG-3 combined with mixture partner dimesulfazet. 195. A composition having a compound selected from AIG-3 combined with mixture partner dimethenamid. 196. A composition having a compound selected from AIG-3 combined with mixture partner dimethenamid-P. 197. A composition having a compound selected from AIG-3 combined with mixture partner dimethoate. 198. A composition having a compound selected from AIG-3 combined with mixture partner dimethylvinphos. 199. A composition having a compound selected from AIG-3 combined with mixture partner dimoxystrobin. 200. A composition having a compound selected from AIG-3 combined with mixture partner dimpropyridaz. 201. A composition having a compound selected from AIG-3 combined with mixture partner diniconazole-M. 202. A composition having a compound selected from AIG-3 combined with mixture partner dinotefuran. 203. A composition having a compound selected from AIG-3 combined with mixture partner diofenolan. 204. A composition having a compound selected from AIG-3 combined with mixture partner dioxopyritrione. 205. A composition having a compound selected from AIG-3 combined with mixture partner dipymetitrone. 206. A composition having a compound selected from AIG-3 combined with mixture partner disulfoton. 207. A composition having a compound selected from AIG-3 combined with mixture partner DNOC. 208. A composition having a compound selected from AIG-3 combined with mixture partner d- trans allethrin. 209. A composition having a compound selected from AIG-3 combined with mixture partner emamectin. 210. A composition having a compound selected from AIG-3 combined with mixture partner emamectin benzoate. 211. A composition having a compound selected from AIG-3 combined with mixture partner empenthrin. 212. A composition having a compound selected from AIG-3 combined with mixture partner endosulfan. 213. A composition having a compound selected from AIG-3 combined with mixture partner enoxastrobin. 214. A composition having a compound selected from AIG-3 combined with mixture partner EPN. 215. A composition having a compound selected from AIG-3 combined with mixture partner epocholeone. 216. A composition having a compound selected from AIG-3 combined with mixture partner epoxiconazole. 217. A composition having a compound selected from AIG-3 combined with mixture partner epsilon-metofluthrin. 218. A composition having a compound selected from AIG-3 combined with mixture partner epsilon-momfluorothrin. 219. A composition having a compound selected from AIG-3 combined with mixture partner epyrifenacil. 220. A composition having a compound selected from AIG-3 combined with mixture partner ergocalciferol. 221. A composition having a compound selected from AIG-3 combined with mixture partner esfenvalerate. 222. A composition having a compound selected from AIG-3 combined with mixture partner ethaboxam. 223. A composition having a compound selected from AIG-3 combined with mixture partner ethametsulfuron. 224. A composition having a compound selected from AIG-3 combined with mixture partner ethiofencarb. 225. A composition having a compound selected from AIG-3 combined with mixture partner ethion. 226. A composition having a compound selected from AIG-3 combined with mixture partner ethiprole. 227. A composition having a compound selected from AIG-3 combined with mixture partner ethoprophos. 228. A composition having a compound selected from AIG-3 combined with mixture partner ethoxysulfuron. 229. A composition having a compound selected from AIG-3 combined with mixture partner etobenzanid. 230. A composition having a compound selected from AIG-3 combined with mixture partner etofenprox. 231. A composition having a compound selected from AIG-3 combined with mixture partner etoxazole. 232. A composition having a compound selected from AIG-3 combined with mixture partner famoxadone. 233. A composition having a compound selected from AIG-3 combined with mixture partner famphur. 234. A composition having a compound selected from AIG-3 combined with mixture partner fenamidone. 235. A composition having a compound selected from AIG-3 combined with mixture partner fenaminstrobin. 236. A composition having a compound selected from AIG-3 combined with mixture partner fenamiphos. 237. A composition having a compound selected from AIG-3 combined with mixture partner fenazaquin. 238. A composition having a compound selected from AIG-3 combined with mixture partner fenbuconazole. 239. A composition having a compound selected from AIG-3 combined with mixture partner fenbutatin oxide. 240. A composition having a compound selected from AIG-3 combined with mixture partner fenhexamid. 241. A composition having a compound selected from AIG-3 combined with mixture partner fenitrothion. 242. A composition having a compound selected from AIG-3 combined with mixture partner fenmezoditiaz. 243. A composition having a compound selected from AIG-3 combined with mixture partner fenobucarb. 244. A composition having a compound selected from AIG-3 combined with mixture partner fenoxanil. 245. A composition having a compound selected from AIG-3 combined with mixture partner fenoxasulfone. 246. A composition having a compound selected from AIG-3 combined with mixture partner fenoxycarb. 247. A composition having a compound selected from AIG-3 combined with mixture partner fenpicoxamid. 248. A composition having a compound selected from AIG-3 combined with mixture partner fenpropathrin. 249. A composition having a compound selected from AIG-3 combined with mixture partner fenpyrazamine. 250. A composition having a compound selected from AIG-3 combined with mixture partner fenpyrazone. 251. A composition having a compound selected from AIG-3 combined with mixture partner fenpyroximate. 252. A composition having a compound selected from AIG-3 combined with mixture partner fenquinotrione. 253. A composition having a compound selected from AIG-3 combined with mixture partner fenthion. 254. A composition having a compound selected from AIG-3 combined with mixture partner fentrazamide. 255. A composition having a compound selected from AIG-3 combined with mixture partner fenvalerate. 256. A composition having a compound selected from AIG-3 combined with mixture partner feproxydim. 257. A composition having a compound selected from AIG-3 combined with mixture partner fipronil. 258. A composition having a compound selected from AIG-3 combined with mixture partner flazasulfuron. 259. A composition having a compound selected from AIG-3 combined with mixture partner flometoquin. 260. A composition having a compound selected from AIG-3 combined with mixture partner flonicamid. 261. A composition having a compound selected from AIG-3 combined with mixture partner florasulam. 262. A composition having a compound selected from AIG-3 combined with mixture partner florpyrauxifen. 263. A composition having a compound selected from AIG-3 combined with mixture partner florylpicoxamid. 264. A composition having a compound selected from AIG-3 combined with mixture partner fluacrypyrim. 265. A composition having a compound selected from AIG-3 combined with mixture partner fluazaindolizine. 266. A composition having a compound selected from AIG-3 combined with mixture partner fluazolate. 267. A composition having a compound selected from AIG-3 combined with mixture partner fluazuron. 268. A composition having a compound selected from AIG-3 combined with mixture partner flubendiamide. 269. A composition having a compound selected from AIG-3 combined with mixture partner flubeneteram. 270. A composition having a compound selected from AIG-3 combined with mixture partner flucarbazone. 271. A composition having a compound selected from AIG-3 combined with mixture partner flucetosulfuron. 272. A composition having a compound selected from AIG-3 combined with mixture partner fluchloraminopyr. 273. A composition having a compound selected from AIG-3 combined with mixture partner fluchlordiniliprole. 274. A composition having a compound selected from AIG-3 combined with mixture partner flucycloxuron. 275. A composition having a compound selected from AIG-3 combined with mixture partner flucythrinate. 276. A composition having a compound selected from AIG-3 combined with mixture partner fludioxonil. 277. A composition having a compound selected from AIG-3 combined with mixture partner fluensulfone. 278. A composition having a compound selected from AIG-3 combined with mixture partner flufenacet. 279. A composition having a compound selected from AIG-3 combined with mixture partner flufenerim. 280. A composition having a compound selected from AIG-3 combined with mixture partner flufenoxadiazam. 281. A composition having a compound selected from AIG-3 combined with mixture partner flufenoximacil. 282. A composition having a compound selected from AIG-3 combined with mixture partner flufenoxuron. 283. A composition having a compound selected from AIG-3 combined with mixture partner flufenoxystrobin. 284. A composition having a compound selected from AIG-3 combined with mixture partner flufenprox. 285. A composition having a compound selected from AIG-3 combined with mixture partner flufenpyr. 286. A composition having a compound selected from AIG-3 combined with mixture partner flufiprole. 287. A composition having a compound selected from AIG-3 combined with mixture partner fluhexafon. 288. A composition having a compound selected from AIG-3 combined with mixture partner fluindapyr. 289. A composition having a compound selected from AIG-3 combined with mixture partner flumethrin. 290. A composition having a compound selected from AIG-3 combined with mixture partner flumetover. 291. A composition having a compound selected from AIG-3 combined with mixture partner flumetsulam. 292. A composition having a compound selected from AIG-3 combined with mixture partner flumetylsulforim. 293. A composition having a compound selected from AIG-3 combined with mixture partner flumiclorac. 294. A composition having a compound selected from AIG-3 combined with mixture partner flumioxazin. 295. A composition having a compound selected from AIG-3 combined with mixture partner flumipropyn. 296. A composition having a compound selected from AIG-3 combined with mixture partner flumorph. 297. A composition having a compound selected from AIG-3 combined with mixture partner fluopicolide. 298. A composition having a compound selected from AIG-3 combined with mixture partner fluopimomide. 299. A composition having a compound selected from AIG-3 combined with mixture partner fluopyram. 300. A composition having a compound selected from AIG-3 combined with mixture partner fluoxapiprolin. 301. A composition having a compound selected from AIG-3 combined with mixture partner fluoxastrobin. 302. A composition having a compound selected from AIG-3 combined with mixture partner fluoxytioconazole. 303. A composition having a compound selected from AIG-3 combined with mixture partner flupentiofenox. 304. A composition having a compound selected from AIG-3 combined with mixture partner flupoxam. 305. A composition having a compound selected from AIG-3 combined with mixture partner flupropacil. 306. A composition having a compound selected from AIG-3 combined with mixture partner flupyradifurone. 307. A composition having a compound selected from AIG-3 combined with mixture partner flupyrimin. 308. A composition having a compound selected from AIG-3 combined with mixture partner flupyroxystrobin. 309. A composition having a compound selected from AIG-3 combined with mixture partner flupyrsulfuron. 310. A composition having a compound selected from AIG-3 combined with mixture partner fluquinconazole. 311. A composition having a compound selected from AIG-3 combined with mixture partner fluroxypyr. 312. A composition having a compound selected from AIG-3 combined with mixture partner flusulfinam. 313. A composition having a compound selected from AIG-3 combined with mixture partner fluthiacet. 314. A composition having a compound selected from AIG-3 combined with mixture partner flutianil. 315. A composition having a compound selected from AIG-3 combined with mixture partner fluxametamide. 316. A composition having a compound selected from AIG-3 combined with mixture partner fluxapyroxad. 317. A composition having a compound selected from AIG-3 combined with mixture partner foramsulfuron. 318. A composition having a compound selected from AIG-3 combined with mixture partner formetanate. 319. A composition having a compound selected from AIG-3 combined with mixture partner fosthiazate. 320. A composition having a compound selected from AIG-3 combined with mixture partner furametpyr. 321. A composition having a compound selected from AIG-3 combined with mixture partner furathiocarb. 322. A composition having a compound selected from AIG-3 combined with mixture partner furilazole. 323. A composition having a compound selected from AIG-3 combined with mixture partner gamma-cyhalothrin. 324. A composition having a compound selected from AIG-3 combined with mixture partner glufosinate-P. 325. A composition having a compound selected from AIG-3 combined with mixture partner glyphosate. 326. A composition having a compound selected from AIG-3 combined with mixture partner halauxifen. 327. A composition having a compound selected from AIG-3 combined with mixture partner halfenprox. 328. A composition having a compound selected from AIG-3 combined with mixture partner halofenozide. 329. A composition having a compound selected from AIG-3 combined with mixture partner halosulfuron. 330. A composition having a compound selected from AIG-3 combined with mixture partner heptafluthrin. 331. A composition having a compound selected from AIG-3 combined with mixture partner heptenophos. 332. A composition having a compound selected from AIG-3 combined with mixture partner hexaflumuron. 333. A composition having a compound selected from AIG-3 combined with mixture partner hexythiazox. 334. A composition having a compound selected from AIG-3 combined with mixture partner hydramethylnon. 335. A composition having a compound selected from AIG-3 combined with mixture partner hydroprene. 336. A composition having a compound selected from AIG-3 combined with mixture partner icafolin. 337. A composition having a compound selected from AIG-3 combined with mixture partner imazamox. 338. A composition having a compound selected from AIG-3 combined with mixture partner imazapic. 339. A composition having a compound selected from AIG-3 combined with mixture partner imazapyr. 340. A composition having a compound selected from AIG-3 combined with mixture partner imazosulfuron. 341. A composition having a compound selected from AIG-3 combined with mixture partner imicyafos. 342. A composition having a compound selected from AIG-3 combined with mixture partner imidacloprid. 343. A composition having a compound selected from AIG-3 combined with mixture partner imiprothrin. 344. A composition having a compound selected from AIG-3 combined with mixture partner indanofan. 345. A composition having a compound selected from AIG-3 combined with mixture partner indazapyroxamet. 346. A composition having a compound selected from AIG-3 combined with mixture partner indaziflam. 347. A composition having a compound selected from AIG-3 combined with mixture partner indolauxipyr. 348. A composition having a compound selected from AIG-3 combined with mixture partner indoxacarb. 349. A composition having a compound selected from AIG-3 combined with mixture partner inpyrfluxam. 350. A composition having a compound selected from AIG-3 combined with mixture partner iodosulfuron. 351. A composition having a compound selected from AIG-3 combined with mixture partner iofensulfuron. 352. A composition having a compound selected from AIG-3 combined with mixture partner ipconazole. 353. A composition having a compound selected from AIG-3 combined with mixture partner ipfencarbazone. 354. A composition having a compound selected from AIG-3 combined with mixture partner ipfentrifluconazole. 355. A composition having a compound selected from AIG-3 combined with mixture partner ipflufenoquin. 356. A composition having a compound selected from AIG-3 combined with mixture partner iprovalicarb. 357. A composition having a compound selected from AIG-3 combined with mixture partner iptriazopyrid. 358. A composition having a compound selected from AIG-3 combined with mixture partner isocycloseram. 359. A composition having a compound selected from AIG-3 combined with mixture partner isofenphos. 360. A composition having a compound selected from AIG-3 combined with mixture partner isofetamid. 361. A composition having a compound selected from AIG-3 combined with mixture partner isoflualanam. 362. A composition having a compound selected from AIG-3 combined with mixture partner isoflucypram. 363. A composition having a compound selected from AIG-3 combined with mixture partner isoprocarb. 364. A composition having a compound selected from AIG-3 combined with mixture partner isopyrazam. 365. A composition having a compound selected from AIG-3 combined with mixture partner isotianil. 366. A composition having a compound selected from AIG-3 combined with mixture partner isoxachlortole. 367. A composition having a compound selected from AIG-3 combined with mixture partner isoxadifen. 368. A composition having a compound selected from AIG-3 combined with mixture partner isoxaflutole. 369. A composition having a compound selected from AIG-3 combined with mixture partner isoxathion. 370. A composition having a compound selected from AIG-3 combined with mixture partner kadethrin. 371. A composition having a compound selected from AIG-3 combined with mixture partner kappa-bifenthrin. 372. A composition having a compound selected from AIG-3 combined with mixture partner kappa-tefluthrin. 373. A composition having a compound selected from AIG-3 combined with mixture partner karetazan. 374. A composition having a compound selected from AIG-3 combined with mixture partner kinoprene. 375. A composition having a compound selected from AIG-3 combined with mixture partner kresoxim-methyl. 376. A composition having a compound selected from AIG-3 combined with mixture partner lambda-cyhalothrin. 377. A composition having a compound selected from AIG-3 combined with mixture partner lancotrione. 378. A composition having a compound selected from AIG-3 combined with mixture partner ledprona. 379. A composition having a compound selected from AIG-3 combined with mixture partner lepimectin. 380. A composition having a compound selected from AIG-3 combined with mixture partner lufenuron. 381. A composition having a compound selected from AIG-3 combined with mixture partner malathion. 382. A composition having a compound selected from AIG-3 combined with mixture partner mancozeb. 383. A composition having a compound selected from AIG-3 combined with mixture partner mandestrobin. 384. A composition having a compound selected from AIG-3 combined with mixture partner mandipropamid. 385. A composition having a compound selected from AIG-3 combined with mixture partner MCPA. 386. A composition having a compound selected from AIG-3 combined with mixture partner mecarbam. 387. A composition having a compound selected from AIG-3 combined with mixture partner mefenoxam. 388. A composition having a compound selected from AIG-3 combined with mixture partner mefenpyr. 389. A composition having a compound selected from AIG-3 combined with mixture partner mefentrifluconazole. 390. A composition having a compound selected from AIG-3 combined with mixture partner meperfluthrin. 391. A composition having a compound selected from AIG-3 combined with mixture partner mepronil. 392. A composition having a compound selected from AIG-3 combined with mixture partner meptyldinocap. 393. A composition having a compound selected from AIG-3 combined with mixture partner mesosulfuron. 394. A composition having a compound selected from AIG-3 combined with mixture partner mesotrione. 395. A composition having a compound selected from AIG-3 combined with mixture partner metaflumizone. 396. A composition having a compound selected from AIG-3 combined with mixture partner metalaxyl. 397. A composition having a compound selected from AIG-3 combined with mixture partner metalaxyl-M. 398. A composition having a compound selected from AIG-3 combined with mixture partner metamifop. 399. A composition having a compound selected from AIG-3 combined with mixture partner metarylpicoxamid. 400. A composition having a compound selected from AIG-3 combined with mixture partner metazosulfuron. 401. A composition having a compound selected from AIG-3 combined with mixture partner metcamifen. 402. A composition having a compound selected from AIG-3 combined with mixture partner metconazole. 403. A composition having a compound selected from AIG-3 combined with mixture partner methamidophos. 404. A composition having a compound selected from AIG-3 combined with mixture partner methenamine. 405. A composition having a compound selected from AIG-3 combined with mixture partner methidathion. 406. A composition having a compound selected from AIG-3 combined with mixture partner methiocarb. 407. A composition having a compound selected from AIG-3 combined with mixture partner methiozolin (cancelled). 408. A composition having a compound selected from AIG-3 combined with mixture partner methomyl. 409. A composition having a compound selected from AIG-3 combined with mixture partner methoprene. 410. A composition having a compound selected from AIG-3 combined with mixture partner methoxychlor. 411. A composition having a compound selected from AIG-3 combined with mixture partner methoxyfenozide. 412. A composition having a compound selected from AIG-3 combined with mixture partner methylneodecanamide. 413. A composition having a compound selected from AIG-3 combined with mixture partner metobenzuron. 414. A composition having a compound selected from AIG-3 combined with mixture partner metofluthrin. 415. A composition having a compound selected from AIG-3 combined with mixture partner metolcarb. 416. A composition having a compound selected from AIG-3 combined with mixture partner metominostrobin. 417. A composition having a compound selected from AIG-3 combined with mixture partner metosulam. 418. A composition having a compound selected from AIG-3 combined with mixture partner metproxybicyclone. 419. A composition having a compound selected from AIG-3 combined with mixture partner metrafenone. 420. A composition having a compound selected from AIG-3 combined with mixture partner metsulfuron. 421. A composition having a compound selected from AIG-3 combined with mixture partner metyltetraprole. 422. A composition having a compound selected from AIG-3 combined with mixture partner mevinphos. 423. A composition having a compound selected from AIG-3 combined with mixture partner milbemectin. 424. A composition having a compound selected from AIG-3 combined with mixture partner mivorilaner. 425. A composition having a compound selected from AIG-3 combined with mixture partner modoflaner. 426. A composition having a compound selected from AIG-3 combined with mixture partner momfluorothrin. 427. A composition having a compound selected from AIG-3 combined with mixture partner monocrotophos. 428. A composition having a compound selected from AIG-3 combined with mixture partner myclobutanil. 429. A composition having a compound selected from AIG-3 combined with mixture partner naled. 430. A composition having a compound selected from AIG-3 combined with mixture partner napropamide-M. 431. A composition having a compound selected from AIG-3 combined with mixture partner nicobifen. 432. A composition having a compound selected from AIG-3 combined with mixture partner nicofluprole. 433. A composition having a compound selected from AIG-3 combined with mixture partner nicosulfuron. 434. A composition having a compound selected from AIG-3 combined with mixture partner nitenpyram. 435. A composition having a compound selected from AIG-3 combined with mixture partner nithiazine. 436. A composition having a compound selected from AIG-3 combined with mixture partner nitrapyrin. 437. A composition having a compound selected from AIG-3 combined with mixture partner novaluron. 438. A composition having a compound selected from AIG-3 combined with mixture partner noviflumuron. 439. A composition having a compound selected from AIG-3 combined with mixture partner omethoate. 440. A composition having a compound selected from AIG-3 combined with mixture partner orthosulfamuron. 441. A composition having a compound selected from AIG-3 combined with mixture partner orysastrobin. 442. A composition having a compound selected from AIG-3 combined with mixture partner oxadiargyl. 443. A composition having a compound selected from AIG-3 combined with mixture partner oxamyl. 444. A composition having a compound selected from AIG-3 combined with mixture partner oxasulfuron. 445. A composition having a compound selected from AIG-3 combined with mixture partner oxathiapiprolin. 446. A composition having a compound selected from AIG-3 combined with mixture partner oxaziclomefone. 447. A composition having a compound selected from AIG-3 combined with mixture partner oxazosulfyl. 448. A composition having a compound selected from AIG-3 combined with mixture partner oxpoconazole. 449. A composition having a compound selected from AIG-3 combined with mixture partner oxydemeton-methyl. 450. A composition having a compound selected from AIG-3 combined with mixture partner parathion. 451. A composition having a compound selected from AIG-3 combined with mixture partner parathion-methyl. 452. A composition having a compound selected from AIG-3 combined with mixture partner penflufen. 453. A composition having a compound selected from AIG-3 combined with mixture partner penoxsulam. 454. A composition having a compound selected from AIG-3 combined with mixture partner penthiopyrad. 455. A composition having a compound selected from AIG-3 combined with mixture partner pentoxazone. 456. A composition having a compound selected from AIG-3 combined with mixture partner permethrin. 457. A composition having a compound selected from AIG-3 combined with mixture partner pethoxamid. 458. A composition having a compound selected from AIG-3 combined with mixture partner phenothrin. 459. A composition having a compound selected from AIG-3 combined with mixture partner phenthoate. 460. A composition having a compound selected from AIG-3 combined with mixture partner phorate. 461. A composition having a compound selected from AIG-3 combined with mixture partner phosalone. 462. A composition having a compound selected from AIG-3 combined with mixture partner phosmet. 463. A composition having a compound selected from AIG-3 combined with mixture partner phosphamidon. 464. A composition having a compound selected from AIG-3 combined with mixture partner phosphocarb. 465. A composition having a compound selected from AIG-3 combined with mixture partner phoxim. 466. A composition having a compound selected from AIG-3 combined with mixture partner picarbutrazox. 467. A composition having a compound selected from AIG-3 combined with mixture partner picloram. 468. A composition having a compound selected from AIG-3 combined with mixture partner picolinafen. 469. A composition having a compound selected from AIG-3 combined with mixture partner picoxystrobin. 470. A composition having a compound selected from AIG-3 combined with mixture partner pinoxaden. 471. A composition having a compound selected from AIG-3 combined with mixture partner pioxaniliprole. 472. A composition having a compound selected from AIG-3 combined with mixture partner piperflanilide. 473. A composition having a compound selected from AIG-3 combined with mixture partner pirimicarb. 474. A composition having a compound selected from AIG-3 combined with mixture partner pirimiphos-methyl. 475. A composition having a compound selected from AIG-3 combined with mixture partner polyoxorim. 476. A composition having a compound selected from AIG-3 combined with mixture partner prallethrin. 477. A composition having a compound selected from AIG-3 combined with mixture partner profenofos. 478. A composition having a compound selected from AIG-3 combined with mixture partner profluazol. 479. A composition having a compound selected from AIG-3 combined with mixture partner profluthrin. 480. A composition having a compound selected from AIG-3 combined with mixture partner profoxydim. 481. A composition having a compound selected from AIG-3 combined with mixture partner prohydrojasmon. 482. A composition having a compound selected from AIG-3 combined with mixture partner pronitridine. 483. A composition having a compound selected from AIG-3 combined with mixture partner propargite. 484. A composition having a compound selected from AIG-3 combined with mixture partner propetamphos. 485. A composition having a compound selected from AIG-3 combined with mixture partner propiconazole. 486. A composition having a compound selected from AIG-3 combined with mixture partner propoxur. 487. A composition having a compound selected from AIG-3 combined with mixture partner propoxycarbazone. 488. A composition having a compound selected from AIG-3 combined with mixture partner propyrisulfuron. 489. A composition having a compound selected from AIG-3 combined with mixture partner propyzamide. 490. A composition having a compound selected from AIG-3 combined with mixture partner proquinazid. 491. A composition having a compound selected from AIG-3 combined with mixture partner prosulfuron. 492. A composition having a compound selected from AIG-3 combined with mixture partner prothioconazole. 493. A composition having a compound selected from AIG-3 combined with mixture partner prothiofos. 494. A composition having a compound selected from AIG-3 combined with mixture partner protrifenbute. 495. A composition having a compound selected from AIG-3 combined with mixture partner pydiflumetofen. 496. A composition having a compound selected from AIG-3 combined with mixture partner pyflubumide. 497. A composition having a compound selected from AIG-3 combined with mixture partner pymetrozine. 498. A composition having a compound selected from AIG-3 combined with mixture partner pyraclofos. 499. A composition having a compound selected from AIG-3 combined with mixture partner pyraclonil. 500. A composition having a compound selected from AIG-3 combined with mixture partner pyraclostrobin. 501. A composition having a compound selected from AIG-3 combined with mixture partner pyraflufen. 502. A composition having a compound selected from AIG-3 combined with mixture partner pyrafluprole. 503. A composition having a compound selected from AIG-3 combined with mixture partner pyrametostrobin. 504. A composition having a compound selected from AIG-3 combined with mixture partner pyraoxystrobin. 505. A composition having a compound selected from AIG-3 combined with mixture partner pyrapropoyne. 506. A composition having a compound selected from AIG-3 combined with mixture partner pyraquinate. 507. A composition having a compound selected from AIG-3 combined with mixture partner pyrasulfotole. 508. A composition having a compound selected from AIG-3 combined with mixture partner pyraziflumid. 509. A composition having a compound selected from AIG-3 combined with mixture partner pyrethrum. 510. A composition having a compound selected from AIG-3 combined with mixture partner pyribencarb. 511. A composition having a compound selected from AIG-3 combined with mixture partner pyrienzoxim. 512. A composition having a compound selected from AIG-3 combined with mixture partner pyridaben. 513. A composition having a compound selected from AIG-3 combined with mixture partner pyridachlometyl. 514. A composition having a compound selected from AIG-3 combined with mixture partner pyridafol. 515. A composition having a compound selected from AIG-3 combined with mixture partner pyridalyl. 516. A composition having a compound selected from AIG-3 combined with mixture partner pyridaphenthion. 517. A composition having a compound selected from AIG-3 combined with mixture partner pyriflubenzoxim. 518. A composition having a compound selected from AIG-3 combined with mixture partner pyrifluquinazon. 519. A composition having a compound selected from AIG-3 combined with mixture partner pyriftalid. 520. A composition having a compound selected from AIG-3 combined with mixture partner pyrimethanil. 521. A composition having a compound selected from AIG-3 combined with mixture partner pyrimidifen. 522. A composition having a compound selected from AIG-3 combined with mixture partner pyriminobac. 523. A composition having a compound selected from AIG-3 combined with mixture partner pyriminostrobin. 524. A composition having a compound selected from AIG-3 combined with mixture partner pyrimisulfan. 525. A composition having a compound selected from AIG-3 combined with mixture partner pyriofenone. 526. A composition having a compound selected from AIG-3 combined with mixture partner pyriprole. 527. A composition having a compound selected from AIG-3 combined with mixture partner pyriproxyfen. 528. A composition having a compound selected from AIG-3 combined with mixture partner pyrisoxazole. 529. A composition having a compound selected from AIG-3 combined with mixture partner pyrithiobac. 530. A composition having a compound selected from AIG-3 combined with mixture partner pyroxasulfone. 531. A composition having a compound selected from AIG-3 combined with mixture partner pyroxsulam. 532. A composition having a compound selected from AIG-3 combined with mixture partner quinalphos. 533. A composition having a compound selected from AIG-3 combined with mixture partner quinofumelin. 534. A composition having a compound selected from AIG-3 combined with mixture partner quinoxyfen. 535. A composition having a compound selected from AIG-3 combined with mixture partner quizalofop-P. 536. A composition having a compound selected from AIG-3 combined with mixture partner rescalure. 537. A composition having a compound selected from AIG-3 combined with mixture partner resmethrin. 538. A composition having a compound selected from AIG-3 combined with mixture partner rimisoxafen. 539. A composition having a compound selected from AIG-3 combined with mixture partner rimsulfuron. 540. A composition having a compound selected from AIG-3 combined with mixture partner rotenone. 541. A composition having a compound selected from AIG-3 combined with mixture partner saflufenacil. 542. A composition having a compound selected from AIG-3 combined with mixture partner seboctylamine. 543. A composition having a compound selected from AIG-3 combined with mixture partner sedaxane. 544. A composition having a compound selected from AIG-3 combined with mixture partner silafluofen. 545. A composition having a compound selected from AIG-3 combined with mixture partner silthiofam. 546. A composition having a compound selected from AIG-3 combined with mixture partner simeconazole. 547. A composition having a compound selected from AIG-3 combined with mixture partner sintofen. 548. A composition having a compound selected from AIG-3 combined with mixture partner S- metolachlor. 549. A composition having a compound selected from AIG-3 combined with mixture partner spidoxamat. 550. A composition having a compound selected from AIG-3 combined with mixture partner spiflumetofen. 551. A composition having a compound selected from AIG-3 combined with mixture partner spinetoram. 552. A composition having a compound selected from AIG-3 combined with mixture partner spinosad. 553. A composition having a compound selected from AIG-3 combined with mixture partner spirobudifen. 554. A composition having a compound selected from AIG-3 combined with mixture partner spirodiclofen. 555. A composition having a compound selected from AIG-3 combined with mixture partner spiromesifen. 556. A composition having a compound selected from AIG-3 combined with mixture partner spiropidion. 557. A composition having a compound selected from AIG-3 combined with mixture partner spirotetramat. 558. A composition having a compound selected from AIG-3 combined with mixture partner spiroxamine. 559. A composition having a compound selected from AIG-3 combined with mixture partner sulcotrione. 560. A composition having a compound selected from AIG-3 combined with mixture partner sulfentrazone. 561. A composition having a compound selected from AIG-3 combined with mixture partner sulfiflumin. 562. A composition having a compound selected from AIG-3 combined with mixture partner sulfluramid. 563. A composition having a compound selected from AIG-3 combined with mixture partner sulfosulfuron. 564. A composition having a compound selected from AIG-3 combined with mixture partner sulfotep. 565. A composition having a compound selected from AIG-3 combined with mixture partner sulfoxaflor. 566. A composition having a compound selected from AIG-3 combined with mixture partner tau-fluvalinate. 567. A composition having a compound selected from AIG-3 combined with mixture partner tebuconazole. 568. A composition having a compound selected from AIG-3 combined with mixture partner tebufenozide. 569. A composition having a compound selected from AIG-3 combined with mixture partner tebufenpyrad. 570. A composition having a compound selected from AIG-3 combined with mixture partner tebufloquin. 571. A composition having a compound selected from AIG-3 combined with mixture partner tebupirimfos. 572. A composition having a compound selected from AIG-3 combined with mixture partner teflubenzuron. 573. A composition having a compound selected from AIG-3 combined with mixture partner tefluthrin. 574. A composition having a compound selected from AIG-3 combined with mixture partner tefuryltrione. 575. A composition having a compound selected from AIG-3 combined with mixture partner tembotrione. 576. A composition having a compound selected from AIG-3 combined with mixture partner temephos. 577. A composition having a compound selected from AIG-3 combined with mixture partner tepraloxydim. 578. A composition having a compound selected from AIG-3 combined with mixture partner terbufos. 579. A composition having a compound selected from AIG-3 combined with mixture partner tetflupyrolimet. 580. A composition having a compound selected from AIG-3 combined with mixture partner tetrachlorantraniliprole. 581. A composition having a compound selected from AIG-3 combined with mixture partner tetrachlorvinphos. 582. A composition having a compound selected from AIG-3 combined with mixture partner tetradifon. 583. A composition having a compound selected from AIG-3 combined with mixture partner tetramethrin. 584. A composition having a compound selected from AIG-3 combined with mixture partner tetramethylfluthrin. 585. A composition having a compound selected from AIG-3 combined with mixture partner tetraniliprole. 586. A composition having a compound selected from AIG-3 combined with mixture partner thenylchlor. 587. A composition having a compound selected from AIG-3 combined with mixture partner theta-cypermethrin. 588. A composition having a compound selected from AIG-3 combined with mixture partner thiabendazole. 589. A composition having a compound selected from AIG-3 combined with mixture partner thiacloprid. 590. A composition having a compound selected from AIG-3 combined with mixture partner thiamethoxam. 591. A composition having a compound selected from AIG-3 combined with mixture partner thiazopyr. 592. A composition having a compound selected from AIG-3 combined with mixture partner thidiazimin. 593. A composition having a compound selected from AIG-3 combined with mixture partner thiencarbazone. 594. A composition having a compound selected from AIG-3 combined with mixture partner thifluzamide. 595. A composition having a compound selected from AIG-3 combined with mixture partner thiocyclam. 596. A composition having a compound selected from AIG-3 combined with mixture partner thiodicarb. 597. A composition having a compound selected from AIG-3 combined with mixture partner thiofanox. 598. A composition having a compound selected from AIG-3 combined with mixture partner thiometon. 599. A composition having a compound selected from AIG-3 combined with mixture partner thiosultap. 600. A composition having a compound selected from AIG-3 combined with mixture partner thiosultap-sodium. 601. A composition having a compound selected from AIG-3 combined with mixture partner thiram. 602. A composition having a compound selected from AIG-3 combined with mixture partner tiadinil. 603. A composition having a compound selected from AIG-3 combined with mixture partner tiafenacil. 604. A composition having a compound selected from AIG-3 combined with mixture partner tigolaner. 605. A composition having a compound selected from AIG-3 combined with mixture partner tiorantraniliprole. 606. A composition having a compound selected from AIG-3 combined with mixture partner tioxazafen. 607. A composition having a compound selected from AIG-3 combined with mixture partner tolfenpyrad. 608. A composition having a compound selected from AIG-3 combined with mixture partner tolprocarb. 609. A composition having a compound selected from AIG-3 combined with mixture partner tolpyralate. 610. A composition having a compound selected from AIG-3 combined with mixture partner topramezone. 611. A composition having a compound selected from AIG-3 combined with mixture partner tralkoxydim. 612. A composition having a compound selected from AIG-3 combined with mixture partner tralomethrin. 613. A composition having a compound selected from AIG-3 combined with mixture partner tralopyril. 614. A composition having a compound selected from AIG-3 combined with mixture partner transfluthrin. 615. A composition having a compound selected from AIG-3 combined with mixture partner triafamone. 616. A composition having a compound selected from AIG-3 combined with mixture partner triazamate. 617. A composition having a compound selected from AIG-3 combined with mixture partner triaziflam. 618. A composition having a compound selected from AIG-3 combined with mixture partner triazophos. 619. A composition having a compound selected from AIG-3 combined with mixture partner tribufos. 620. A composition having a compound selected from AIG-3 combined with mixture partner trichlorfon. 621. A composition having a compound selected from AIG-3 combined with mixture partner triclopyr. 622. A composition having a compound selected from AIG-3 combined with mixture partner triclopyricarb. 623. A composition having a compound selected from AIG-3 combined with mixture partner trifloxystrobin. 624. A composition having a compound selected from AIG-3 combined with mixture partner trifloxysulfuron. 625. A composition having a compound selected from AIG-3 combined with mixture partner trifludimoxazin. 626. A composition having a compound selected from AIG-3 combined with mixture partner trifluenfuronate. 627. A composition having a compound selected from AIG-3 combined with mixture partner triflumezopyrim. 628. A composition having a compound selected from AIG-3 combined with mixture partner triflumuron. 629. A composition having a compound selected from AIG-3 combined with mixture partner triflusulfuron. 630. A composition having a compound selected from AIG-3 combined with mixture partner trimethacarb. 631. A composition having a compound selected from AIG-3 combined with mixture partner trinexapac. 632. A composition having a compound selected from AIG-3 combined with mixture partner tripyrasulfone. 633. A composition having a compound selected from AIG-3 combined with mixture partner triticonazole. 634. A composition having a compound selected from AIG-3 combined with mixture partner tritosulfuron. 635. A composition having a compound selected from AIG-3 combined with mixture partner tyclopyrazoflor. 636. A composition having a compound selected from AIG-3 combined with mixture partner umifoxolaner. 637. A composition having a compound selected from AIG-3 combined with mixture partner uniconazole-P. 638. A composition having a compound selected from AIG-3 combined with mixture partner valifenalate. 639. A composition having a compound selected from AIG-3 combined with mixture partner vamidothion. 640. A composition having a compound selected from AIG-3 combined with mixture partner vaniliprole. 641. A composition having a compound selected from AIG-3 combined with mixture partner XMC. 642. A composition having a compound selected from AIG-3 combined with mixture partner xylylcarb. 643. A composition having a compound selected from AIG-3 combined with mixture partner zeta-cypermethrin. 644. A composition having a compound selected from AIG-3 combined with mixture partner zoxamide. 645. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is about 50000:1 to about 1:50000. 646. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is about 40000:1 to about 1:40000. 647. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is about 10256:1 to about 1:10256. 648. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is about 10000:1 to about 1:10000. 649. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is about 2564:1 to about 1:2564. 650. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 1000:1 to about 1:1000. 651. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is about 640:1 to about 1:640. 652. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 500:1 to about 1:500. 653. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 100:1 to about 1:100. 654. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 50:1 to about 1:50. 655. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 20:1 to about 1:20. 656. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is about 16:1 to about 1:16. 657. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 10:1 to about 1:10. 658. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 5:1 to about 1:5. 659. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 3:1 to about 1:3. 660. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 2:1 to about 1:2. 661. A composition according to any of the previous details from 1 through 644 wherein the weight ratio of said compound to said mixture partner is 1:1. 662. A composition according to any of the previous details from 1 through 661 wherein the composition further comprises a source of ammonia selected from the group consisting of anhydrous ammonia, ammonium nitrate, ammonium sulfate, urea ammonium nitrate, urea, manure, and mixtures thereof. S TMS 662. A composition and a source of ammonia selected from the group consisting of anhydrous nitrate, ammonium sulfate, urea ammonium nitrate, urea, manure, and mixtures thereof. In some aspects, compositions disclosed herein may exhibit enhanced efficacy may be expected when a compound is combined with a mixture partner at particular weight ratios within the ranges defined above. “Enhanced efficacy” in this context means an efficacy greater than the expected efficacy as calculated by the Colby equation. Application of Nitrification Inhibitor Compounds to Soil In certain aspects provided herein one or more nitrification inhibitor compounds or compositions are mixed with a source of ammonia. Sources of ammonia include, but are not limited to, anhydrous ammonium, ammonium salts, such as ammonium nitrate, calcium ammonium nitrate, ammonium sulfate nitrate, ammonium sulfate or ammonium phosphate; organic ammonia sources, such as manure, biogas, worm castings, compost, seaweed or guano; urea-containing fertilizers such as, urea, formaldehyde urea, urea ammonium nitrate solution, urea sulfur, urea ammonium sulfate, or other urea-based fertilizers. In certain aspects provided herein, one or more of the nitrification inhibitor compounds or compositions are mixed with anhydrous ammonia, which is then injected into the soil. In other aspects, the compound or composition is injected separately into the growing medium at the time of anhydrous ammonia application. The amount of compound or composition present in the anhydrous ammonia mixture, or directly injected, may be adjusted so that an agriculturally effective amount of the nitrification-inhibiting compound or composition is spread. In certain aspects provided herein, the nitrification inhibitor compound or composition is mixed with fertilizers such as urea-ammonium nitrate solution to form a urea-ammonium nitrate nitrification-inhibitor mixture. These mixtures may also include other ingredients such as herbicides, insecticides, fungicides, and safeners. Such mixtures may be applied at rates of from about 10 to about 70 gallons per acre depending on the fertilizer strength and concentration as well as the target amount of nitrogen per acre. For example, the amount of compound or composition present in the treated mixture may be adjusted so that an agriculturally effective amount of the compound or composition is spread. In certain aspects provided herein, the nitrification compound or composition is impregnated on dry urea. The amount of compound or composition impregnated will depend upon the application rate of the urea. For example, urea may be spread at a rate of from about 200 to about 700 pounds per acre. An amount of compound or composition may be impregnated on dry urea so that the compound or composition is spread at an agriculturally effective amount. In certain aspects provided herein, the compound or composition is spread as part of a manure slurry mixture. The compound or composition may be mixed with manure prior to application or may be separately applied. The amount of compound or composition present in a manure slurry may be adjusted so that an agriculturally effective amount of compound or composition is spread. A compound or composition may be applied to a growing medium at a rate of from about 50 grams per acre to about 4 kilograms per acre. A compound may be applied to a growing medium at the following rates: 50-60 grams / acre; 60-70 grams / acre; 70-80 grams / acre; 80-90 grams / acre; 90-100 grams / acre; 100-120 grams / acre; 120-140 grams / acre; 140-160 grams / acre; 160-180 grams / acre; 180-200 grams / acre; 200-225 grams / acre; 225-250 grams / acre; 250-275 grams / acre; 275-300 grams / acre; 300-350 grams / acre; 350-400 grams / acre; 400-450 grams / acre; 450-500 grams / acre; 500-550 grams / acre; 550-600 grams / acre; 600-650 grams / acre; 650-700 grams / acre; 700-750 grams / acre; 750-800 grams / acre; 800-850 grams / acre; 850-900 grams / acre; 900-950 grams / acre; 950-1000 grams / acre; 1.0-1.1 kilograms / acre; 1.1-1.2 kilograms / acre; 1.2-1.3 kilograms / acre; 1.3-1.4 kilograms / acre; 1.4-1.5 kilograms / acre; 1.5-1.6 kilograms / acre; 1.6-1.7 kilograms / acre; 1.7-1.8 kilograms / acre; 1.8-1.9 kilograms / acre; 1.9-2.0 kilograms / acre; 2.0-2.2 kilograms / acre; 2.2-2.4 kilograms / acre; 2.4-2.6 kilograms / acre; 2.6-2.8 kilograms / acre; 2.8-3.0 kilograms / acre; 3.0-3.2 kilograms / acre; 3.2-3.4 kilograms / acre; 3.4-3.6 kilograms / acre; 3.6-3.8 kilograms / acre; and 3.8-4.0 kilograms / acre. Experimental General Synthesis Procedures General Procedure 1 To a stirred solution of the heterocyclic (1 equiv) 0.7 g, 3.95 mmol, in EtOAc (0.2 mmolar ) were added Et3N(4 equiv.) and CuI (5 mol%) at RT (room temperature) and the reaction mixture was degassed with argon for 5 min, followed by addition of TMS-acetylene (4.5 equiv.) and bis(triphenylphosphine)palladium chloride (15 mol%). The reaction mixture was stirred at 50 °C for 16h. After completion of the reaction (monitor by TLC), the reaction mixture was filtered through celite pad, the filtrate was dried over Na2SO4and concentrated under reduced pressure. The crude product was purified by flash column chromatography using 10 - 20% EtOAc in petroleum ether to afford the desired products. General Procedure 2 To a stirred solution of the ethynyl TMS heterocycle (1.0 eq) in methanol (0.2 mmolar) was added 1 equiv. potassium carbonate. The reaction was stirred at room temperature until completion of the reaction (monitor by TLC). The reaction mixture was filtered through celite pad, the filtrate was dried over Na2SO4and concentrated under reduced pressure. The crude product was purified by flash column chromatography using 10 - 20% EtOAc in petroleum ether to afford the desired products. General Procedure 3 Aldehyde (1.0 equiv.) was a dissolved in anhydrous methanol (0.2-0.5 mM) and charged with cesium carbonate (1.0 equiv.) and cooled to 0-5 degrees C. Dimethyl (l-diazo-2-oxopropyl) phosphonate (1.0 equiv.) was added dropwise after which the reaction was allowed to stir for 1- 18h after which the crude mixture was concentrated onto silica gel and purified directly by flash silica gel chromatography to provide the desired alkyne. Synthesis Procedures 12780973 Trimethylsilylacetylene, (1.5 mL, 10.81 mmol), bis(triphenylphosphine)palladium(II) chloride (79 mg, 0.113 mmol) and copper(I) iodide (4.29 mg, 0.023 mmol) was added to a degassed solution of methyl 2-bromo-1,3-thiazole-5-carboxylate (500 mg, 2.252 mmol) and Et3N (1.4 mL, 9.68 mmol) in EtOAc (2.0 mL). The mixture was heated to 50 °C for 7h before cooling to 25 °C and filtering the reaction mixture through celite. The solvent was evaporated under reduced pressure to obtain the desired product. 12791843 To a solution of 1-(4-(trifluoromethyl)-2-((trimethylsilyl)ethynyl)thiazol-5-yl)ethan-1-one (0.4 g, 1.37 mmol) in MeOH (5 mL) was added NaBH4(0.025 g, 0.68 mmol) at 0 °C and stirred for 1h at same temperature. Water (10 mL) added to reaction mixture and extracted with DCM, washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 20 - 25% EtOAc in petroleum ether to afford 0.2 g (65%) of target an off white solid; M P 73 – 77 °C;1H NMR (400 MHz, CDCl3) δ 5.48 – 5.45 (m, 1H), 3.50 (s, 1H), 2.44 – 2.43 (m, 1H), 1.60 – 1.58 (m, 3H);19F NMR (376 MHz, CDCl3) δ -60.41; ESIMS m / z 222.07 ([M+H]+). 12791845 To a solution of 4-(trifluoromethyl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide 0.2 g, 0.68 mmol) in THF-H2O mixture (3:1) (5 mL) was added LiOH.H2O (0.03 g, 0.68 mmol) and the reaction mixture was stirred for 2h at RT. The reaction mixture was acidified with 1N HCl and extracted with DCM. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 60 - 70% EtOAc in petroleum ether to afford 0.035 g (23%) of target, a pale brown solid; M P 134 - 138 °C;1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.14 (s, 1H), 5.24 (s, 1H);19F NMR (376 MHz, CDCl3) δ -60.27; ESIMS m / z 221.06 ([M+H]+). 12791847 To a solution of ethyl 2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide 0.1 g, 0.44 mmol) in THF-H2O mixture (3:1) (5 mL) was added LiOH.H2O (0.02 g, 0.44 mmol) and the reaction mixture was stirred for 2h at RT. The reaction mixture was acidified with 1N HCl and extracted with DCM. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 0.03 g (44%) of target, a pale brown solid; M P 178 - 182 °C;1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.26 (s, 1H), 7.80 (s, 1H), 5.08 (s, 1H); ESIMS m / z 153.01 ([M+H]+). 12791857 To a solution of 1-(2-ethynylthiazol-5-yl)ethan-1-one (0.1 g, 0.66 mmol) in MeOH (3 mL) was added NaBH4(0.013 g, 0.33 mmol) at 0 °C and stirred for 1h at same temperature. Water (10 mL) added to reaction mixture and extracted with DCM, washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 20 - 25% EtOAc in petroleum ether to afford 0.09 g (89%) of target, a brown solid; M P 72 – 76 °C;1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 5.21 – 5.15 (m, 1H), 3.45 (s, 1H), 2.20 – 2.19 (m, 1H), 1.63 – 1.60 (m, 3H); ESIMS m / z 154.03 ([M+H]+). 12791863 To a solution ethyl 2-ethynylthiazole-5-carboxylate (1.4 g, 5.53 mmol) in THF:H2O mixture (3:1) (15 mL) was added LiOH.H2O (0.28 g, 6.64 mmol) and the reaction mixture was stirred at RT for 16h. The reaction mixture was acidified with 1N HCl (pH ~ 2) and was extracted with DCM. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 0.8 g (72%) of target, a black solid; M P 195 - 199 °C;1H NMR (400 MHz, DMSO-d6) δ 13.30 (brs, 1H), 8.54 (s, 1H), 5.02 (s, 1H); ESIMS m / z 153.99 ([M+H]+). 12791865 To a solution of 2-ethynylthiazole-5-carboxylic acid (0.25 g, 1.63 mmol) in DMF (5 mL) was added HATU (0.745 g, 1.96 mmol), DIPEA (0.315 g, 2.45 mmol), NH4Cl (0.1 g, 1.96 mmol) and the reaction mixture was stirred for 16h at RT. The reaction mixture was diluted with water (20 mL) and was extracted with EtOAc. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 50 - 60% EtOAc in petroleum ether to afford 0.17 g (66%) of target, an off white solid; M P 162 - 166 °C;1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.88 (s, 1H), 7.65 (s, 1H), 5.02 (s, 1H); ESIMS m / z 153.02 ([M+H]+). 12791867 To a solution of 2-ethynylthiazole-4-carboxylic acid (0.25 g, 1.63 mmol) in DMF (5 mL) was added HATU (0.93 g, 2.45 mmol), DIPEA (0.42 g, 3.26 mmol), 2-methylbut-3-yn-2-amine (0.16 g, 1.96 mmol) and the reaction mixture was stirred for 16h at RT. The reaction mixture was diluted with water (20 mL) and was extracted with EtOAc. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 30 - 40% EtOAc in petroleum ether to afford 0.16 g (45%) of target, an off white solid; M P 101 - 105 °C;1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.40 (brs, 1H), 3.53 (s, 1H), 2.38 (s, 1H), 1.76 (s, 3H), 1.75 (s, 3H); ESIMS m / z 219.07 ([M+H]+). 12791869 To a solution of 2-ethynylthiazole-4-carboxylic acid (0.25 g, 1.63 mmol) in DMF (5 mL) was added HATU (0.93 g, 2.45 mmol), DIPEA (0.42 g, 3.26 mmol), 2-methylbut-3-yn-2-amine (0.16 g, 1.96 mmol) and the reaction mixture was stirred for 16h at RT. The reaction mixture was diluted with water (20 mL) and was extracted with EtOAc. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 30 - 40% EtOAc in petroleum ether to afford the product, an off white solid (0.17 g, 54%); M P 121 - 125 °C;1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.47 (brs, 1H), 4.25 - 4.23 (m, 2H), 3.54 (s, 1H), 2.27 - 2.26 (m, 1H); ESIMS m / z 191.03 ([M+H]+). 12795389 To a solution of 2-bromo-N-(2-methylbut-3-yn-2-yl)thiazole-4-carboxamide (0.4 g, 1.46 mmol) in toluene (5 mL) was added CuI (0.03 g, 0.14 mmol) followed by the addition of DIPEA (0.37 g, 2.93 mmol), PdCl2(PPh3)2(0.05 g, 0.07 mmol), TMS acetylene (0.18 g, 1.75 mmol) under argon atmosphere and the reaction mixture was stirred at 70 °C for 16h. The reaction mixture was cooled to RT, EtOAc (30 mL) was added, filtered through a pad of celite, the filtrate was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 5 - 10% EtOAc in petroleum ether to afford 0.12 g (28%) of target, a brown liquid; FT-IR 1666.53 cm-1(C=O stretching present);1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.41 (brs, 1H), 2.38 (s, 1H), 1.74 - 1.73 (m, 6H), 0.30 (s, 9H); ESIMS m / z 291.01 ([M+H]+). 12795393 To a solution of 2-bromo-N-(prop-2-yn-1-yl)thiazole-4-carboxamide (0.4 g, 1.46 mmol) in toluene (5 mL) was added CuI (0.03 g, 0.14 mmol) followed by the addition of DIPEA (0.37 g, 2.93 mmol), PdCl2(PPh3)2 (0.05 g, 0.07 mmol), TMS acetylene (0.18 g, 1.75 mmol) under argon atmosphere and the reaction mixture was stirred at 70 °C for 16h. The reaction mixture was cooled to RT, EtOAc (30 mL) was added, filtered through a pad of celite, the filtrate was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 5 - 10% EtOAc in petroleum ether to afford 0.12 g (28%) of target, a pale brown solid (0.11 g, 25%); M P 79 - 83 °C;1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.48 (brs, 1H), 4.24 - 4.21 (m, 2H), 2.26 - 2.24 (m, 1H), 0.30 (s, 9H); ESIMS m / z 263.08 ([M+H]+). 12806737 To a stirred solution of 1-(2-((trimethylsilyl)ethynyl)thiazol-4-yl)prop-2-yn-1-one (0.2 g, 0.80 mmol) in MeOH (2 mL) was added K2CO3(1 mg, cat.) at RT. The reaction mixture was stirred at RT for 5 minutes. After completion of the reaction, the reaction mixture was poured in ice water (5 mL), acidified with 1N HCl (2 mL, pH ~4) and extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10 % EtOAc in petroleum ether eluent to afford the product, a pale brown solid (0.032 g, 27%); M P 126 - 130 °C;1H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 3.56 (s, 1H), 3.50 (s, 1H); ESIMS m / z 162.08 ([M+H]+). 12806745 To a stirred solution of (E)-1-(2-((trimethylsilyl)ethynyl)thiazol-4-yl)but-2-en-1-one (0.2 g, 0.80 mmol) in MeOH (2 mL) was added K2CO3 (1 mg, cat.) at RT. The reaction mixture was stirred at RT for 5 minutes. After completion of the reaction, the reaction mixture was poured in ice water (5 mL), acidified with 1N HCl (2 mL, pH ~4) and extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10 % EtOAc in petroleum ether eluent to afford a pale brown solid (0.025 g, 17%); M P 111 - 115 °C;1H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 7.23 - 7.14 (m, 1H), 6.77 - 6.72 (m, 1H), 3.63 (s, 1H); 2.03 (t, J = 3.4 Hz, 3H); ESIMS m / z 178.09 ([M+H]+). 12806753 To a stirred solution of 1-(2-((trimethylsilyl)ethynyl)thiazol-5-yl)prop-2-yn-1-one (1.2 g, 5.76 mmol) in DCM (15 mL) was added DMP (3.17 g, 7.49 mmol) at 0 °C. The reaction mixture was stirred at RT for 3h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 24g) using 10 - 20% EtOAc in petroleum ether eluent to afford the product, a brown solid (0.2 g, 50%); M P 78 - 82 °C;1H NMR (400 MHz, CDCl3) δ 8.50 (s, 1H), 3.45 (s, 1H), 0.30 (s, 9H); ESIMS m / z 234.11 ([M+H]+). 12806761 To a stirred solution of (E)-1-(2-((trimethylsilyl)ethynyl)thiazol-4-yl)but-2-en-1-one (0.2 g, 0.80 mmol) in MeOH (2 mL) was added K2CO3(1 mg, cat.) at RT. The reaction mixture was stirred at RT for 5 minutes. After completion of the reaction, the reaction mixture was poured in ice water (5 mL), acidified with 1N HCl (2 mL, pH ~4) and extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10 % EtOAc in petroleum ether eluent to afford target (0.025 g, 21%), a pale brown solid (0.025 g, 17%); M P 111 - 115 °C;1H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 7.23 - 7.14 (m, 1H), 6.77 - 6.72 (m, 1H), 3.63 (s, 1H); 2.03 (t, J = 3.4 Hz, 3H); ESIMS m / z 178.09 ([M+H]+). 12811457 1 mL MeOH was added to N-(pentan-3-yl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (63 mg, 0.21 mmol), K2CO3 (58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to get product (40 mg, 86%), a yellow solid. 12811461 1 mL MeOH was added to N-(pentan-3-yl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (63 mg, 0.21 mmol), K2CO3(58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to get product (40 mg, 83%), a brown solid. 12811465 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidephenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4 (62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product, a yellow solid. 12811467 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidephenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4(62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product, a yellow solid. 12811469 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidephenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4 (62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product, a yellow solid. 12811471 Under N2, 2-bromo-N-methylthiazole-5-carboxamide (0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4(62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product N-methyl-2- ((trimethylsilyl)ethynyl)thiazole-5-carboxamide, a brown solid (63%).1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 6.14 (s, 1H), 3.01 (d, J = 4.8 Hz, 3H), 0.29 (s, 9H).13C NMR (101 MHz, 155-156 °C. 12811481 1 mL MeOH was added to N-methyl-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (0.21 mmol), K2CO3(58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to get product provide the desired product, a brown solid (55 mg, 98%)1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 6.25 (s, 1H), 3.57 (s, 1H), 3.01 (d, J = 4.9 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 160.22, 150.49, 142.97, 136.16, 84.05, 75.97, 26.90. ESIMS m / z 167 ([M+H]+). Mp, 118-119 °C. 12811473 1 mL MeOH was added to N-(pentan-3-yl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (63 mg, 0.21 mmol), K2CO3(58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to get product (40 mg, 86%), a brown solid. 12811475 1 mL MeOH was added to N-(pentan-3-yl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (63 mg, 0.21 mmol), K2CO3(58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to get product (40 mg, 86%), a brown solid. 12811477 1 mL MeOH was added to N-(pentan-3-yl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (63 mg, 0.21 mmol), K2CO3(58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to get product (40 mg, 86%), a brown solid.1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 5.70 (s, 1H), 4.01 - 3.92 (m, 1H), 3.56 (s, 1H), 1.70 - 1.61 (m, 2H), 1.54 - 1.45 (m, 2H), 0.95 (t, J = 7.4 Hz, 6H).13C NMR (101 MHz, CDCl3) δ 159.30, 150.41, 142.57, 136.71, 83.90, 76.03, 67.98, 53.11, 27.48, 10.29. ESIMS m / z 223 ([M+H]+). Mp, 81-82 °C. 12811479 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidephenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4(62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product 1 (161mg, 64%), a brown solid. 12811481 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidephenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4(62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3 (1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product 1 (114 mg, 72%), a brown solid. 12811485 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidephenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4(62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product 1 (150 mg, 49%), a white solid. 12776911 To a solution of ethyl 2-bromooxazole-4-carboxylate L-a (1.5 g, 6.81 mmol) in toluene (10 mL) was added CuI (0.13 g, 0.0.68 mmol), DIPEA (1.75 g, 13.62 mmol), PdCl2(PPh3)2(0.24 g, 0.34 mmol) and trimethylsilylacetylene (1 g, 10.21 mmol) under argon atmosphere and the reaction mixture was stirred at 50 °C for 16h. The reaction mixture was cooled to RT, EtOAc (150 mL) was added and filtered through pad of celite and filtrate was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 5 - 10% EtOAc in petroleum ether to afford 0.8 g (50%) of target, a brown liquid; FT-IR 1737.89 cm-1(C=O stretching present);1H NMR (400 MHz, CDCl3) δ 8.16 (s, 3H), 4.39 (q, J = 7.2 Hz, 2H), 1.38 (t, J = 7.2 Hz, 3H), 0.27 (s, 9H); ESIMS m / z 238.22 ([M+H]+). 12776913 To a solution of 2-ethynyloxazole-4-carboxylic acid (0.8 g, 3.37 mmol) in THF-H2O mixture (3:1) (10 mL) was added LiOH.H2O (0.14 g, 3.37 mmol) and the reaction mixture was stirred for 2h at RT. The reaction mixture was acidified with 1N HCl and extracted with DCM. The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 0.6 g (86%) of target, a brown solid; M P 161 – 165 °C;1H NMR (400 MHz, DMSO-d6) δ 13.35 (bs, 1H), 8.83 (s, 1H), 4.95 (s, 1H); ESIMS m / z 138.16 ([M+H]+). 12776915 To a solution of 2-ethynyloxazole-4-carboxylic acid (0.1 g, 0.72 mmol) and amine input (0.073 g, 0.87 mmol) in DMF (3 mL), was added HATU (0.42 g, 1.09 mmol) and DIPEA (0.19 g, 1.44 mmol) at 0 °C and the reaction mixture was stirred for 16h at RT. The reaction mixture diluted with water (20 mL), was extracted with EtOAc. The organic layer was washed with ice water, brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 30 - 35% EtOAc in petroleum ether to afford 0.08 g (54%) of target, a brown solid. 12776921 To a solution of 2-ethynyloxazole-5-carboxylic acid (0.35 g, 2.55 mmol) and amine input (0.318 g, 3.83 mmol) in DMF (5 mL), was added HATU (1.45 g, 3.82 mmol) and DIPEA (0.98 g, 7.66 mmol) at 0 °C and the reaction mixture was stirred for 16h at RT. The reaction mixture diluted with water (30 mL), was extracted with EtOAc. The organic layer was washed with ice water, brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 20 - 25% EtOAc in petroleum ether to afford 0.240 g (46%) of product, an off white solid; M P 133 – 137 °C;1H NMR (400 MHz, CDCl3) δ 7.70 (s, 1H), 6.30 (s, 1H), 3.33 (s, 1H), 2.41 (s, 1H), 1.75 (s, 6H); ESIMS m / z 203.13 ([M+H]+). 12776925 To a solution of ethyl ethyl 2-iodooxazole-5-carboxylate h1 (2.5 g, 9.36 mmol) in toluene (25 mL) was added CuI (0.178 g, 0.93 mmol), DIPEA (2.4 g, 18.72 mmol), PdCl2(PPh3)2(0.33 g, 0.468 mmol) and trimethylsilylacetylene (1.8 g, 18.72 mmol) under argon atmosphere and the reaction mixture was stirred at 50 °C for 16h. The reaction mixture was cooled to RT. EtOAc (100 mL) was added and filtered through pad of celite and filtrate was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 5 - 10% EtOAc in petroleum ether to afford 1 g (45%) of product, a brown liquid; FT-IR 1733.07 cm-1(C=O stretching present);1H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H), 4.39 (q, J = 7.2 Hz, 2H), 1.38 (t, J = 7.2 Hz, 3H), 0.28 (s, 9H); ESIMS m / z 238.15 ([M+H]+). 12791853 To a solution of 2-ethynyloxazole-4-carboxamide (0.3 g, 2.18 mmol) and Aq. NH3(2 mL) in THF (5 mL), was added HATU (1 g, 2.62 mmol) and DIPEA (0.42 g, 3.28 mmol) at 0 °C and the reaction mixture was stirred for 16h at RT. The reaction mixture diluted with water (20 mL), was extracted with EtOAc. The organic layer was washed with ice water, brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel 100 - 200 mesh) eluting with 40 - 45% EtOAc in petroleum ether to afford 0.05 g (42%) of product, a pale brown solid; M P 176 – 180 °C;1H NMR (400 MHz, DMSO-d6) δ 8.65 (s, 1H), 7.79 (s, 1H), 7.58 (s, 1H), 4.95 (s, 1H); ESIMS m / z 137.12 ([M+H]+). 12797705 To a stirred solution of 2-((trimethylsilyl)ethynyl)oxazole-4-carbaldehyde (0.2 g, 0.80 mmol) in MeOH (2 mL) was added K2CO3(1 mg, cat.) at RT. The reaction mixture was stirred at RT for 5 minutes. After completion of the reaction, the reaction mixture was poured in ice water (5 mL), acidified with 1N HCl (2 mL, pH ~4) and extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10 % EtOAc in petroleum ether eluent to afford the product, an off white solid (0.078 g, 43%); M P 110 - 114 °C;1H NMR (400 MHz, CDCl3) δ 9.93 (s, 1H), 8.24 (s, 1H), 3.33 (s, 1H); ESIMS m / z 122.12 ([M+H]+). 12806755 To a stirred solution of 1-(2-((trimethylsilyl)ethynyl)oxazol-4-yl)prop-2-yn-1-ol (0.27 g, 1.14 mmol) in dichloromethane (6 mL) was added DMP (0.63 g, 1.49 mmol) at 0 °C. The reaction mixture was stirred at RT for 3h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 24 g) using 10 % EtOAc in petroleum ether eluent to afford the product, a pale brown solid (0.12 g, 42%); M P 75 - 79 °C;1H NMR (400 MHz, CDCl3) δ 8.29 (s, 1H), 3.44 (s, 1H), 0.29 (s, 9H); ESIMS m / z 218.15 ([M+H]+). 12806763 To a stirred solution of 1-(2-((trimethylsilyl)ethynyl)oxazol-4-yl)prop-2-yn-1-one (0.2 g, 0.80 mmol) in MeOH (2 mL) was added K2CO3(1 mg, cat.) at RT. The reaction mixture was stirred at RT for 5 minutes. After completion of the reaction, the reaction mixture was poured in ice water (5 mL), acidified with 1N HCl (2 mL, pH ~4) and extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10 % EtOAc in petroleum ether eluent to afford a pale brown solid (0.024 g, 45%); M P 117 - 121 °C;1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 3.45 (s, 1H), 3.33 (s, 1H); ESIMS m / z 146.05 ([M+H]+). 12811459 1 mL MeOH was added to N-(pentan-3-yl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (63 mg, 0.21 mmol), K2CO3(58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to get product (25 mg, 86%), a yellow solid. 12811483 1 mL MeOH was added to N-(pentan-3-yl)-2-((trimethylsilyl)ethynyl)thiazole-5-carboxamide (63 mg, 0.21 mmol), K2CO3(58 mg, 0.42 mmol) in 3 mL of THF at 0 °C and the reaction was stirred at 0 °C for 30 min. After the reaction was completed, the mixture was filtered and washed with THF, the filtrate was concentrated under low temperature to the product, a brown solid (85%)1H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), 6.45 (s, 1H), 4.24 (dd, J = 5.4, 2.6 Hz, 2H), 3.35 (s, 1H), 2.31 (t, J = 2.6 Hz, 1H).13C NMR (101 MHz, CDCl3) δ 155.57, 145.61, 145.06, 132.07, 81.61, 78.37, 72.49, 70.68, 29.09. ESIMS m / z 175([M+H]+). Mp, 112-113 °C. 12811491 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidePhenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4 (62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product, a yellow oil. 12811493 Under N2, 2-bromo-N-(pentan-3-yl)thiazole-5-carboxamidePhenyl)benzamide (150 mg, 0.54mmol) was added to trimethylsilylacetylene (317 mg, 3.23 mmol), Pd(PPh3)4 (62 mg, 0.05 mmol), Cul (21 mg, 0.11 mmol), NEt3(1.5 ml) in 4.5 mL of THF. The reaction was stirred at 50 °C for 2h. After the reaction was completed, the mixture was filtered and washed with THF. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate = 5:1) to give the product, a white solid (25%)1H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H), 6.45 (s, 1H), 4.23 (dd, J = 5.4, 2.6 Hz, 2H), 2.30 (t, J = 2.5 Hz, 1H), 0.30 (s, 9H).13C NMR (101 MHz, CDCl3) δ 156.53, 147.07, 145.37, 132.91, 102.42, 91.08, 79.24, 73.24, 29.85. ESIMS m / z 247([M+H]+). Mp, 134-135 °C. 12771961 To a solution of N-(2-methylbut-3-yn-2-yl)-2-(trichloromethyl)-4-(trifluoromethyl)thiazole-5- carboxamide (273 mg, 0.719 mmol) in THF:H20 (5:1, 6 mL) was added Fe(s) in a single portion. The resulting reaction mixture was allowed to warm to 60°C. Maintained the temperature for 16h (start at 4:00 PM). The reaction was monitor by TLC (n-hexane: ethyl acetate 8:2) and LCMS. No SM was visible by TLC after 16h. The reaction mixture was concentrated (nitrogen) and adsorbed onto celite pre-column and chromatographed over silica gel. 12799175 To a solution of 5-ethynylthiazole-2-carbaldehyde ( 40 mg, 0.292 mmol) in anhydrous THF at - 78C was slowly added methylmagnesium bromide (86 µl, 0.292 mmol)as a 3.4 molar solution in THF. After the addition was complete, the reaction was allowed to slowly warm to 25 °C over 30 minutes and then quenched with sat aq NH4Cl and diluted with 50 mL ether. The layers were partitioned and the ether layer was dried over magnesium sulfate and concentrated over a stream of nitrogen to afford a brown residue (42 mg, 85%). 12816775 To a stirred solution of (5-ethynylfuran-2-yl)methanol (0.1 g, 0.82 mmol) in THF (5 mL) were added NaH (60%, 0.078 g, 1.63 mmol) and CH3I (0.12 mL, 2.04 mmol) at 0 °C. The reaction mixture was stirred at RT for 2h. After completion of the reaction (monitor by TLC), the reaction mixture was poured into water (10 mL) and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12g) using 5 - 10% EtOAc in petroleum ether to afford product (0.026 g, 23%) a pale brown liquid; FT IR 2111.13 cm-1(C≡C Stretching present);1H NMR (400 MHz, CDCl3) δ 6.60 (d, J = 3.2 Hz, 1H), 6.31 (d, J = 3.6 Hz, 1H), 4.37 (s, 2H), 3.38 (s, 3H), 3.37 (s, 1H); ESIMS m / z 135.9 ([M]+). 12816797 To a stirred solution of 1-(5-ethynylfuran-2-yl)ethan-1-ol (0.1 g, 0.60 mmol) in DMF (5 mL) was added K2CO3(0.1 g, 0.73 mmol) and methyl iodide (0.1 mL, 1.20 mmol) at RT. The reaction mixture was stirred at RT for 16h. After completion of the reaction (monitor by TLC), the reaction mixture was poured into water (10 mL) and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10 - 20% EtOAc in petroleum ether to afford the product, a brown liquid (0.026 g, 26%); FT IR 3288.69 cm-1(O-H Stretching present);1H NMR (400 MHz, CDCl3) δ 6.59 (d, J = 3.6 Hz, 1H), 6.22 (dd, J = 0.4, 3.2 Hz, 1H), 4.86 (q, J = 4.4 Hz, 1H), 3.39 (s, 1H), 1.92 (d, J = 4.4 Hz, 1H), 1.54 (d, J = 6.8 Hz, 3H); ESIMS m / z 135.9 ([M]+). 12830209 To a stirred solution of 1-(2-ethynyloxazol-4-yl)ethan-1-ol (0.1 g, 0.72 mmol) in THF (5 mL) was added NaH (48 mg, 0.72 mmol) at 0 °C and stirred for 15 minutes at 0 °C, followed by the addition of CH3I (0.091 mL, 1.45 mmol). The reaction mixture was slowly warmed to RT and stirred for 2h. After completion of the reaction (monitor by TLC), the reaction mixture was quenched with cold water (10 mL) and extracted with EtOAc. The combined organic layers were dried over Na2SO4and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 24 g) using 10-20% EtOAc in petroleum ether eluent to afford Product-A8 (0.036 g, 33%) a pale yellow liquid; FT IR 2121.70 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 4.36 (q, J = 6.0 Hz, 1H), 3.36 (s, 3H), 3.23 (s, 1H), 1.48 (d, J = 6.4 Hz, 3H);13C NMR (101 MHz, CDCl3) δ 145.58, 143.86, 135.94, 79.91, 72.18, 71.29, 56.66, 20.13; ESIMS m / z 152.07 ([M+H]+). 12830213 To a stirred solution of 1-(2-((trimethylsilyl)ethynyl)oxazol-4-yl)ethan-1-one (0.3 g, 1.55 mmol) in THF (10 mL) was added CH3MgI [3M in Diethyl ether (0.6 mL, 1.86 mmol)] at 0 °C. The reaction mixture was stirred at RT for 3h. After completion of the reaction (monitor by TLC), the reaction mixture was quenched with saturated NH4Cl (20 mL) and extracted with EtOAc). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 24 g) using 10-20% EtOAc in petroleum ether eluent to afford Int-A-1-5 (0.2 g, 59%) a pale yellow liquid; FT IR 2175.70 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 4.83 (q, J = 6.8 Hz, 1H), 2.15 (d, J = 4.8 Hz, 1H), 1.52 (d, J = 6.4 Hz, 3H), 0.27 (d, 9H); ESIMS m / z 210.18 ([M+H]+). 12853673 To a stirred solution of thiazole-2-thiol (0.3 g, 2.56 mmol) in acetone (10 mL) were added K2CO3(0.35 g, 2.56 mmol) and propargyl bromide (0.2 mL, 2.56 mmol) at 0°C. The reaction mixture was stirred at RT for 3h. After completion (monitor by TLC) of the reaction, the reaction mixture was poured in water (10 mL) and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford product (0.15 g, 38%), a brown liquid; FT IR 2117.84 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 3.2 Hz, 1H), 7.28 (d, J = 3.2 Hz, 1H), 3.95 (d, J = 2.8 Hz, 2H), 2.28 (t, J = 5.2 Hz, 1H); ESIMS m / z 156.12 ([M+H]+). 12853681 To a stirred solution of 2-bromothiazole (0.3 g, 1.82 mmol) in 1,4-dioxane (10 mL) were added LiCl (0.23 g, 5.48 mmol) and CuI (0.1 g, 0.55 mmol) at RT. The reaction mixture was degassed with argon for 5 minutes, then added input-1 (0.66 g, 2.01 mmol) and Pd(PPh3)4(0.1 g, 0.09 mmol) at RT. The reaction mixture was stirred at 100 °C for 16h. After completion (monitor by TLC) of the reaction, the reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 5% - 10% EtOAc in petroleum ether to afford product (0.05 g, 22%), a brown liquid; FT IR 2235.50 cm-1(C≡C stretching present);1H NMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 3.2 Hz, 1H), 7.77 (d, J = 3.6 Hz, 1H), 2.14 (s, 3H); ESIMS m / z 123.92 ([M+H]+). 12853683 To a stirred solution of 2-bromothiazole (1 g, 6.09 mmol) in EtOAc (20 mL) were added Et3N (3.6 mL, 26.21 mmol) and CuI (12 mg, 0.06 mmol) at RT. The reaction mixture was degassed with argon for 5 minutes, then added prop-2-yn-1-ol (input-2) (1.6 mL, 29.26 mmol) and bis(triphenylphosphine)palladium chloride (0.2 g, 0.30 mmol) at RT. The reaction mixture was stirred at 50-55 °C for 16h. After completion (monitor by TLC) of the reaction, the reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10% - 15% EtOAc in petroleum ether to afford product (0.25 g, 29%), a brown liquid; FT IR 2231.64 cm-1(C≡C stretching present);1H NMR (400 MHz, DMSO-d6) δ 7.91 (d, J = 3.6 Hz, 1H), 7.86 (d, J = 3.2 Hz, 1H), 5.53 (t, J = 6.2 Hz, 1H), 4.36 (d, J = 6.0 Hz, 2H); ESIMS m / z 139.94 ([M+H]+). 12853685 To a stirred solution of 2-bromothiazole (1 g, 6.09 mmol) in EtOAc (20 mL) were added Et3N (3.6 mL, 26.21 mmol) and CuI (12 mg, 0.06 mmol) at RT. The reaction mixture was degassed with argon for 5 minutes, then added the alkyne (1.6 mL, 29.26 mmol) and bis(triphenylphosphine)palladium chloride (0.2 g, 0.30 mmol) at RT. The reaction mixture was stirred at 50-55 °C for 16h. After completion (monitor by TLC) of the reaction, the reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10% - 15% EtOAc in petroleum ether to afford the desired product, a brown liquid (0.4 g, 43%); FT IR 2231.64 cm-1(C≡C stretching present);1H NMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 3.2 Hz, 1H), 7.78 (d, J = 3.2 Hz, 1H), 4.99 (t, J = 5.6 Hz, 1H), 3.60 (q, J = 5.6 Hz, 2H), 2.64 (t, J = 6.6 Hz, 2H); ESIMS m / z 153.95 ([M+H]+). 12853687 To a stirred solution of 2-bromothiazole (1 g, 6.09 mmol) in EtOAc (20 mL) were added Et3N (3.6 mL, 26.21 mmol) and CuI (12 mg, 0.06 mmol) at RT. The reaction mixture was degassed with argon for 5 minutes, then added prop-2-yn-1-ol (input-2) (1.6 mL, 29.26 mmol) and bis(triphenylphosphine)palladium chloride (0.2 g, 0.30 mmol) at RT. The reaction mixture was stirred at 50-55 °C for 16h. After completion (monitor by TLC) of the reaction, the reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10% - 15% EtOAc in petroleum ether to afford the product, a Brown liquid (0.1 g, 21%); FT IR 2231.64 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 3.2 Hz, 1H), 7.36 (d, J = 3.6 Hz, 1H), 4.37 (s, 2H), 3.47 (s, 3H); ESIMS m / z 153.1 ([M]+). 12855341 To a stirred solution of 2 bromo thiazole (0.3 g, 2.56 mmol) in Acetone (10 mL) were added K2CO3(0.35 g, 2.56 mmol) and propargyl alcohol (0.2 mL, 2.56 mmol) at 0°C. The reaction mixture was stirred at RT for 3h. After completion (monitor by TLC) of the reaction, the reaction mixture was poured in water (10 mL) and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a colorless liquid (0.03 g, 17%); FT IR 2239.36 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 3.6 Hz, 1H), 6.70 (d, J = 4.0 Hz, 1H), 5.00 (q, J = 2.4 Hz, 2H), 1.89 (t, J = 2.2 Hz, 3H); ESIMS m / z 153.83 ([M+H]+). 12855343 To a stirred solution of 2,4-dibromothiazole (0.5 g, 2.07 mmol) in 1,4-Dioxane (10 mL) were added CsF (0.47 g, 3.11 mmol) at RT. The reaction mixture was degassed with argon for 5 minutes, then added input-1 (0.82 g, 2.48 mmol) and Pd(tBu3P)2(53 mg, 0.11 mmol) at RT. The reaction mixture was stirred at 100 °C for 16h. After completion (monitor by TLC) of the reaction, the reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 5% - 10% EtOAc in petroleum ether to afford product (0.2 g, 41%), a yellow semi solid (0.15 g, 45%); FT IR 2235.50 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.22 (s, 1H), 2.10 (s, 3H), 2.04 (s, 3H); ESIMS m / z 161.88 ([M+H]+). 12856621 3-ethynyl-5-methylisothiazole (1.0 equiv) was a dissolved in anhydrous methanol (0.2-0.5 mM) and charged with cesium carbonate (1.0 equiv) and cooled to 0-5 degrees C. Dimethyl (l-diazo-2- oxopropyl)phosphonate (1.0 equiv) was added dropwise after which the reaction was allowed to stir for 1-18h after which the crude mixture was concentrated onto silica gel and purified directly by flash silica gel chromatography to provide the desired alkyne 12858893 To a stirred solution of TMS acetylene (0.9 mL, 8.01 mmol) in THF (15 mL) was added n-BuLi (2.5M) (3.2 mL, 7.69 mmol) at -78 °C. The reaction mixture was stirred at -78 °C for 30 minutes. Furan-2-carbaldehyde SM-C (0.5 g, 6.41 mmol) was then added into the reaction mixture at -78 °C and stirred for 5h at RT. After completion of the reaction, the reaction mixture was quenched with aq. NH4Cl (10 mL) and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 40 g) using 15% - 20% EtOAc in petroleum ether eluent to afford Int-C1 (0.2 g, 16%), a yellow solid; FT IR 2177.63 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.41 (m, 1H), 6.45 (m, 1H), 6.35 (m, 1H), 5.45 (d, J = 6.8 Hz, 1H), 2.22 (d, J = 7.2 Hz, 1H), 0.21 (s, 9H); ESIMS m / z 194.94 ([M+H]+). Synthesis of 1-(furan-2-yl)-3-(trimethylsilyl)prop-2-yn-1-one: To a stirred solution of 1-(furan-2-yl)-3-(trimethylsilyl)prop-2-yn-1-ol (0.1 g, 0.51 mmol) in DCM (5 mL) was added pyridinium chlorochromate (0.16 g, 0.77 mmol) at RT. The reaction mixture stirred at RT for 16h. After completion (monitor by TLC) of the reaction, the reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 24 g) using 2% - 5% EtOAc in petroleum ether to afford product (0.03 g, 30%), a brown liquid; FT IR 2158.35 cm-1(C≡C stretching present);1H NMR (400 MHz, CDCl3) δ 7.66 (m, 1H), 7.36 (m, 1H), 6.57 (dd, J = 1.6, 3.6 Hz, 1H), 0.29 (s, 9H); ESIMS m / z 192.90 ([M+H]+). General Procedure A Under air, to a 20 mL vial, aryl halide (1 equiv.), triethylamine (3 equiv.) and copper(I) iodide (0.1 equiv.) were charged and diluted with Dioxane (0.3 M concentration of substrate). The reaction was degassed for 5 min, then ethynyltrimethylsilane (4.0 equiv.) and bis(triphenylphosphine)palladium (II) chloride (0.1 equiv.) were added under an inert atmosphere. The vial was placed in a heating block that was warmed to 80 ºC and the solution was stirred for 20 h. The reaction was cooled and passed through a pad of celite. The filtrate was concentrated, and the resulting residue was purified by flash chromatography on silica gel. General Procedure B To a 50 mL RBF charged with TMS-Alkyne (1.0 equiv.), MeOH (0.25 M concentration of substrate) and potassium carbonate (0.2 equiv.) were added. The reaction was stirred at ambient temperature for 30 min. After reaction completion, the reaction was diluted with H2O and extracted with DCM. The combined organics were passed through a phase separator and concentrated. The resulting residue was purified by flash chromatography on silica gel. General Procedure C Aldehyde (1.0 equiv.) was a dissolved in anhydrous methanol (0.2-0.5 mM) and charged with cesium carbonate (1.0 equiv.) and cooled to 0-5 degrees C. Dimethyl (l-diazo-2-oxopropyl) phosphonate (1.0 equiv.) was added dropwise after which the reaction was allowed to stir for 1- 18h after which the crude mixture was concentrated onto silica gel and purified directly by flash silica gel chromatography to provide the desired alkyne. General Procedure D To a 20 mL vial, sodium hydride (60% Wt., 1.0 Equiv.) was charged and diluted with THF (1.0 M concentration of substrate) under an inert atmosphere. Then alcohol (1.0 equiv.) was added at ambient temperature and the reaction was allowed to stir for 30 min. Then aryl halide (1.0 equiv.) in THF (0.5 M concentration of substrate) was added. The vial was placed in a heating block that was warmed to 50 ºC and the solution was stirred for 20 h. The reaction was quenched with Sat NH4Cl and extracted with Et2O. The combined organics were dried over MgSO4, filtered, and concentrated. The resulting residue was purified by flash chromatography on silica gel General Procedure E Under air, a 20 mL vial equipped with a magnetic stirring bar was charged with P(tBu)3Pd G2 (0.03 equiv.) and the aryl halide (1 equiv. if solid). The vial was capped, and the air was purged by evacuating the vial and backfilling with nitrogen three times. Dry DMF was added (0.4 M concentration of substrate) to the vial followed by the aryl halide (1 equiv. if liquid), the TMS- protected alkyne (1.5 equiv.) and TBAF (1.5 equiv., 1 M in THF). The vial was placed in a heating block that was warmed to 80 ºC and the solution was stirred for 20 h. After the reaction time, the vial was opened to air and aqueous Na2CO3was added (4 mL). The crude product was extracted with CH2Cl2and purified by flash chromatography on silica gel. General Procedure F To a 20 mL vial, sodium alkoxide (1.0 equiv.) was charged. Then a solution of aryl halide (1.0 equiv.) in THF (0.2 M concentration of substrate) was added. The vial was placed in a heating block that was warmed to 50 ºC and the solution was stirred for 20 h. The reaction was quenched with saturated NH4Cl and extracted with Et2O. The combined organics were dried over MgSO4, filtered, and concentrated. The resulting residue was purified by flash chromatography on silica gel. General Procedure G A stock solution of [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.1 equiv) in dioxane (2 mL) and copper(I) iodide (0.1 equiv) in dioxane (1 mL) and triethylamine (3 equiv) were added to a vial containing a solution of Br / Cl-heterocycle (1 equiv) in dioxane (2 mL). The contents were sealed and degassed with nitrogen and the overall reaction concentration was 0.2M. With stirring, ethynyltrimethylsilane (2 equiv) was added neat and the contents were heated to 60oC overnight for 18 hours. The reaction was quenched with AcOH (10 equiv), the product mass was observed by LCMS. The contents were diluted with EtOAc and partitioned between 2.5 M KHCO3 (2 x) and brine then dried over MgSO4. The contents were condensed by rotoary evaporation and the residue was purified by silica-gel chromatography eluting with hexanes / EtOAc 10-100% over 10 minutes to yield the product. General Procedure H To a flask containing (trimethylsilyl)ethynyl)-heterocycle was dissolved in a solution of potassium fluoride (0.1M, 2 equiv) in methanol and stirred at ambient temperature for 18 hours. The contents were condensed by rotary evaporation and purified over silica-gel eluting with DCM / MeOH 0- 10% to obtain the product. General Procedure I To a stirring solution of aldehyde (1M, 1 equiv), potassium carbonate (2 equiv) in methanol was added dimethyl (1-diazo-2-oxopropyl)phosphonate (1.1 equiv) neat. Gas evolution was observed. The contents were stirred at ambient temperature for 2 - 5 hours. The contents were diluted with water and extracted with dichloromethane. The pooled organics were dried over MgSO4and condensed by fractional distillation. The residue was purified over a silca-gel column eluting with DCM / MeOH 0-10% over 10 minutes. The fractions containing the product were pooled and evaporated to give the product. Procedure J A nitrogen containing heterocycle posing an alkyne was dissolved in diethyl ether (1M) and treated with an equal volume of 1M acid (HCl or anhydrous H3PO4) in diethyl ether. The volatile components were removed by evaporation using a stream of nitrogen gas to give the desired salt form of the heterocycle. General Procedure K To a stirred solution of 2-bromothiazole (1 g, 6.09 mmol) in EtOAc (20 mL) were added Et3N (3.6 mL, 26.21 mmol) and CuI (12 mg, 0.06 mmol) at RT. The reaction mixture was degassed with argon for 5 minutes, then added prop-2-yn-1-ol (1.6 mL, 29.26 mmol) and bis(triphenylphosphine)palladium chloride (0.2 g, 0.30 mmol) at RT. The reaction mixture was stirred at 50-55 °C for 16 h. After completion (monitor by TLC) of the reaction, the reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 12 g) using 10% - 15% EtOAc in petroleum ether to afford the desired product. General Procedure L To a stirred solution of alkynyl alcohol (0.15 g, 1.07 mmol) in dichloromethane (10 mL) were added Et3N (0.2 mL, 1.60 mmol) and acetyl chloride (0.1 mL, 1.28 mmol) at 0°C. The reaction mixture was stirred at RT for 16 h. After completion (monitor by TLC) of the reaction, the reaction mixture was concentrated under reduced pressure, poured into water and extracted with DCM. The organic layers were dried over anhydrous Na2SO4and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Column size: 24 g) using 10% - 15% EtOAc in petroleum ether to afford the desired product. Procedure M To a stirred solution of thiazole-2-thiol (0.3 g, 2.56 mmol) in Acetone (10 mL) were added K2CO3(0.35 g, 2.56 mmol) and methyl propargyl bromide (0.2 mL, 2.56 mmol) at 0°C. The reaction mixture was stirred at RT for 3 h. After completion (monitor by TLC) of the reaction, the reaction mixture was poured in water (10 mL) and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the desired product. Procedure N To a stirred solution of 3-bromo pyrazole (0.5 g) in Et13121N (5 mL) was added CuI (0.049 g). Then the reaction mixture was degassed with argon gas for 10 mins followed by addition of Pd(PPh3)4(0.148 g) and the acetylated alkyne input (5.14 mmol) at RT. The resultant reaction mixture was stirred at 80 °C for 2 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure at 38 °C to get the crude compound, which was purified by prep-HPLC to give the desired product. Procedure O To a stirred solution of pyrazole (0.5 g) in dry THF (5V) was added NaH (2 eq) and followed by propargyl bromide (1.2 eq) at 0 °C. The resultant reaction mixture was stirred at 0 °C to RT for 3 h. After completion of the reaction, the reaction mixture was quenched with ice-cold water and extracted with ethyl acetate and washed with aqueous NaCl solution and dried over with anhydrous Na2SO4. The resultant solution was concentrated under reduced pressure at 38 °C to get the crude compound, which was purified by combi flash chromatography to afford the desired product. Analytical Methods Synthesized compounds were characterized by the following methods: melting point, ESIMS – electrospray mass spec, HRMS – high resolution mass spec, EIMS – electron ionization mass spec, GCMS – gas chromatography mass spec, SIMS – secondary ion mass spec, Fourier Transform Infrared Spectroscopy – FTIR,1H,13C,19F, and31P Nuclear Magnetic resonance spectroscopy. Chiral structures in Table 1 are indicated by “&1” adjacent to the chiral center. Table 1 Nitrification Inhibiting Compounds Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Material ID Structure Preparation or Source Table 2 Analytical Data Mat. ID M.P. (°C) IR Mass NMR (H, C or F) FT-IR ), ; ), ) , , , ), ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, ), ), s, = ), , ), ), ), 0 ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), ), ), ), ), ), ), ), 5 , Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, Chloroform-d) δ 4.93 0, 3 R 3 2 9 R ), ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), R 6, ), 3) ), J t, ), 4. ), ), 4. ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 1, ), C 8, ), 9 ), ), ), ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) FT-IR ), , ), = 4, ), 9 ), ), ), ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 1H), ) ), ), 1, 8, ), ) ), ), 7, 7 0. 0 ), 8 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, Chloroform-d) δ 8.36 9 2 6 ), ). Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H), = 0 ), = 8 5, 5 R 4 8 R - = 7 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) FT IR = 0 = 6 = ), 2 ), 5 3 2 , ), C 3, 4, – – Mat. ID M.P. (°C) IR Mass NMR (H, C or F) FT - IR:1= 1 , = 0 , ), 3 R ), , = 6 = Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 9.16 (t, J = ), ); = ), 9 – ) = 5 ), = 7 ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 7.57 (s, 2H), ), 1 ), = 5 , , , = 7 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, Chloroform-d) δ 7.46 0. 5 6 8 1 0 6 R = 0 ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, Chloroform-d) δ 7.69 , 6 7 8 ), 3 , 1, 0 = δ 7 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 7.39 (s, 1H), ), ), ), 5, ), 8 ), = 2. Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 8.23 (d, J = 2. 4 = 6, 8, 7 3 0. 1 4 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, Chloroform-d) δ 8.16 , 2 ), 6, = 0 = 6, 7. 8, Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 3 ), ), = 5 = 1 ; = 6 0 , Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, Chloroform-d) δ 8.21 0 J 1 ), ), ), 6 J 3, Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 8.74 (d, J = J s, δ z, ), 9, ), 9, ), 3, 2. ), 7, Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 0, ), 3) ), ), 2, 4, ), 6 = z, , Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 9.05 (d, J = ), ), ), ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = ), ), 6. z, ), z, 7 6 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 8.26 (d, J = ), 8 0 1, ), J 0. ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 1, δ ), ), 0 z, ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 4, ), 7 ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 9.20 (s, 2H), ), ), 4 ), ), ), ), 1 = Mat. ID M.P. (°C) IR Mass NMR (H, C or F) EIMS m / z), δ ), ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H NMR (600 MHz, CDCl3) δ 8.51 (d, J = ), ), 7, 2, ), 9, Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 6, 8, ), , ), 8 ), 9, 9. Mat. ID M.P. (°C) IR Mass NMR (H, C or F) HRMS- = s, s, = 2 = ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, DMSO) δ 7.91 (s, 5 ), ), = 7 s, z ), 5, J , 0 ), C , = 4 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, DMSO) δ 6.21 (s, ), J 1 7, = 9 = 9 – ), C 9, Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), ), 5 ), C 3, 8, ), 7 ), ), ), 3 ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1), J ), s, = 0 = 3 = 3 = 8 ), = 2 ), J ), ), Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), ), ), 4 ), ), ), ), ), ), ), ), ), , Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H), ), ), ), ), J ), J s, ), s, ), , ), - 2 ), , Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1H NMR (400 MHz, CDCl3) δ 9.85 (brs, , = ), 1, ), 3 = Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 9.22 (d, J = 4 3, ), = = = = ), ) Mat. ID M.P. (°C) IR Mass NMR (H, C or F) ESIMS m / z1= ), ). = = = = 0 Mat. ID M.P. (°C) IR Mass NMR (H, C or F) 1H NMR (500 MHz, CDCl3) δ 8.61 (s, 1H), z, s, = = Biological Testing Compound Preparation: Compounds were dissolved in DMSO at 0.1 mM concentrations. Soil Slurry Preparation: Two different soils were sourced from Kalamazoo, Michigan (loamy fine sand) and Windfall, Indiana (clay loam). After collection soils were sieved at 2 mm and stored at 4 °C for no more than 6 months. The slurry is prepared by weighing out 143 grams of field moist soil per liter of nitrification media with a chlorate block (0.8 µM K2HPO4; 0.1 µM KH2PO4; 0.5 µM(NH4)2SO4; 10 µM NaClO3) and stirring it in a Pyrex dish for 5 minutes. Experimental Approach: While stirring, 900 µL of slurry was pipetted into a 96 deep well plate. After slurry addition, 9 µL of 0.1 mM stock solution of a compound or solvent control (i.e., DMSO) was immediately added to the designated well to bring the final concentration to 0.1 µM. A sealing mat was placed on top of the plate and mixed by inverting the plates three times. Plates were incubated for 48 hours at 28°C while shaking sideways at 225 rpm. After 48 hours the plate was spun down at 3,000 rpm for 15 minutes and the supernatant was analyzed for nitrite concentrations using the colorimetric Griess assay. Nitrification rates were determined by the total amount of nitrite formed over the incubation period. Nitrification inhibition was determined by normalizing the nitrification rate by the DMSO control. The relative inhibition of tested compounds was additionally normalized to the reference nitrification inhibitor nitrapyrin. Results are shown in Tables 3 and 4. Table 3 Inhibition of Soil Nitrification. Nitrification Nitrification Nitrification Nitrification Inhibition Inhibition Inhibition Inhibition Nitrification Nitrification Nitrification Nitrification Inhibition Inhibition Inhibition Inhibition Nitrification Nitrification Nitrification Nitrification Inhibition Inhibition Inhibition Inhibition Nitrification Nitrification Nitrification Nitrification Inhibition Inhibition Inhibition Inhibition Nitrification Nitrification Nitrification Nitrification Inhibition Inhibition Inhibition Inhibition Nitrification Nitrification Nitrification Nitrification Inhibition Inhibition Inhibition Inhibition Nitrification Nitrification Nitrification Nitrification Inhibition Inhibition Inhibition Inhibition Table 4. Nitrification Inhibition Soil Fertilizer Test Compound Mean NH4 Nitrification ( / dr il) Inhibiti n Kalamazoo Ammonium 12870263 87.65334647 75% Sulfate Windfall None DMSO 0.60101057 Windfall UAN 12816297 134.3107182 95% Windfall UAN Nitrapyrin 94.13935955 64% Windfall UAN DMSO 6.485130146 1%

Claims

CLAIMS We claim:

1. A nitrification inhibiting composition comprising a carrier; and a compound selected from the group consisting of R1R1R1R N 4. wherein R1-R4are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R1– R4is C≡C or C≡C-TMS; and NN R14Formula IV .wherein R11– R14are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl,C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R11– R14is C≡C or C≡C-TMS; and R23R22R24Formula V .are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R21– R24is C≡C or C≡C-TMS; and R32R Formula VI.– are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen,C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R31– R34is C≡C or C≡C-TMS; andR42N R43.H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R41– R44is C≡C or C≡C-TMS; and SNR53Formula VIII.and R53are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R51, R52, or R53is C≡C or C≡C-TMS; and ONFormula IX, andwherein R61, R62, and R63 are independently H, ethynyl, trimethylsilyl-ethynyl, C1 – C6 alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3,C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH-cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R61, R62, or R63is C≡C or C≡C-TMS; and R71N Formula X.R73, and R74are independently H, ethynyl, trimethylsilyl-ethynyl, C1– C6alkoxy, C1– C6thioalkyl, C1– C6alkyl, C3– C6cycloalkyl, C1– C6alkenyl, C3– C6cycloalkenyl, C1– C6haloalkyl, C1– C6haloalkenyl, C1– C6haloalkyl, C1– C6haloalkoxy, benzyl, CH(OH)CH3, C(=O)NH2, CO2H, CO2Me, CO2Et, C(=O)H, CH2OH, halogen, C(=O)NHCH2C≡C, C(=O)NHCH(CH3)C≡C, C(=O)NHCH(CH2CH3)C≡C, C≡N, C(=O)NHC(CH3)(CH3)C≡C, C(=O)NH-cyclopropyl, C(=O)NH-cyclobutyl, C(=O)NH- cyclopentyl, C(=O)NH-cyclohexyl, C(=O)NHCH(CH3)CH3, C(=O)NHCH(CH3)CH2CH3, C(=O)NHCH(CH2CH3)CH2CH3, C(=O)alkyl, C(=O)haloalkyl, C(=O)CH3, C(=O)Et, C(=O)C=CCH3, C(=O) C≡C, C(=O)N(CH3)CH3, and wherein at least one of R71, R72, R73, or R74is C≡C or C≡C-TMS; and a mixture partner selected from the group consisting of 2,4-D, abamectin, acephate, acequinocyl, acetamiprid, acetoprole, acibenzolar, acrinathrin, acynonapyr, afidopyropen, alanycarb, aldicarb, aldimorph, allethrin, alpha-bromadiolone, alpha-cypermethrin, alpha-endosulfan, ametoctradin, amicarbazone, amidoflumet, amidosulfuron, aminocyclopyrachlor, aminopyralid, aminopyrifen, amisulbrom, amitraz, anisiflupurin, aviglycine, azadirachtin, azafenidin, azamethiphos, azimsulfuron, azinphos-ethyl, azinphos-methyl, azocyclotin, azoxystrobin, beflubutamid, beflubutamid-M, benalaxyl-M, bencarbazone, benclothiaz, bendiocarb, benfuracarb, benquitrione, bensultap, benthiavalicarb, benzfendizone, benzobicyclon, benzovindiflupyr, benzoximate, benzpyrimoxan, beta-cyfluthrin, beta-cypermethrin, bethoxazin, bicyclopyrone, bifenazate, bifenthrin, bioallethrin, bioresmethrin, bipyrazone, bispyribac, bistrifluron,bisulflufen, bixafen, bixlozone, boscalid, broclozone, broflanilide, bromopropylate, bromuconazole, buprofezin, butafenacil, butocarboxim, butoxycarboxim, butroxydim, cadusafos, cafenstrole, carbaryl, carbofuran, carbosulfan, carboxin, carfentrazone, carpropamid, cartap hydrochloride, carvone, chinomethionat, chlorantraniliprole, chlordane, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroinconazide, chloroprallethrin, chlorpyrifos, chlorpyrifos-methyl, cholecalciferol, chromafenozide, cinidon- ethyl, clacyfos, clethodim, clodinafop, clofencet, clofentezine, clopyralid, cloquintocet, cloransulam, clothianidin, copper hydroxide, coumaphos, coumoxystrobin, cumyluron, cyanophos, cyantraniliprole, cyazofamid, cybutryne, cyclanilide, cyclaniliprole, cyclobutrifluram, cycloprothrin, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxaprid, cyenopyrafen, cyetpyrafen, cyflufenamid, cyflumetofen, cyfluthrin, cyhalodiamide, cyhalofop, cyhalothrin, cyhexatin, cymoxanil, cypermethrin, cyphenothrin, cyprodinil, cyproflanilide, cyprosulfamide, cypyrafluone, cyromazine, d-cis-trans allethrin, DDVP, debacarb, deltamethrin, demeton-S-methyl, diafenthiuron, diazinon, dichlobentiazox, dichlorprop-P, dichlorvos, diclocymet, dicloromezotiaz, diclosulam, dicofol, dicrotophos, dicyclanil, dicyclonon, difenoconazole, diflovidazin, diflubenzuron, diflufenzopyr, diflumetorim, dimefluthrin, dimepropyridaz, dimesulfazet, dimethenamid, dimethenamid-P, dimethoate, dimethylvinphos, dimoxystrobin, dimpropyridaz, diniconazole-M, dinotefuran, diofenolan, dioxopyritrione, dipymetitrone, disulfoton, DNOC, d-trans allethrin, emamectin, emamectin benzoate, empenthrin, endosulfan, enoxastrobin, EPN, epocholeone, epoxiconazole, epsilon-metofluthrin, epsilon-momfluorothrin, epyrifenacil, ergocalciferol, esfenvalerate, ethaboxam, ethametsulfuron, ethiofencarb, ethion, ethiprole, ethoprophos, ethoxysulfuron, etobenzanid, etofenprox, etoxazole, famoxadone, famphur, fenamidone, fenaminstrobin, fenamiphos, fenazaquin, fenbuconazole, fenbutatin oxide, fenhexamid, fenitrothion, fenmezoditiaz, fenobucarb, fenoxanil, fenoxasulfone, fenoxycarb, fenpicoxamid, fenpropathrin, fenpyrazamine, fenpyrazone, fenpyroximate, fenquinotrione, fenthion, fentrazamide, fenvalerate, feproxydim, fipronil, flazasulfuron, flometoquin, flonicamid, florasulam, florpyrauxifen, florylpicoxamid, fluacrypyrim, fluazaindolizine, fluazolate, fluazuron, flubendiamide, flubeneteram, flucarbazone, flucetosulfuron, fluchloraminopyr, fluchlordiniliprole, flucycloxuron, flucythrinate, fludioxonil, fluensulfone, flufenacet, flufenerim, flufenoxadiazam, flufenoximacil, flufenoxuron, flufenoxystrobin, flufenprox, flufenpyr, flufiprole, fluhexafon, fluindapyr, flumethrin,flumetover, flumetsulam, flumetylsulforim, flumiclorac, flumioxazin, flumipropyn, flumorph, fluopicolide, fluopimomide, fluopyram, fluoxapiprolin, fluoxastrobin, fluoxytioconazole, flupentiofenox, flupoxam, flupropacil, flupyradifurone, flupyrimin, flupyroxystrobin, flupyrsulfuron, fluquinconazole, fluroxypyr, flusulfinam, fluthiacet, flutianil, fluxametamide, fluxapyroxad, foramsulfuron, formetanate, fosthiazate, furametpyr, furathiocarb, furilazole, gamma-cyhalothrin, glufosinate-P, glyphosate, halauxifen, halfenprox, halofenozide, halosulfuron, heptafluthrin, heptenophos, hexaflumuron, hexythiazox, hydramethylnon, hydroprene, icafolin, imazamox, imazapic, imazapyr, imazosulfuron, imicyafos, imidacloprid, imiprothrin, indanofan, indazapyroxamet, indaziflam, indolauxipyr, indoxacarb, inpyrfluxam, iodosulfuron, iofensulfuron, ipconazole, ipfencarbazone, ipfentrifluconazole, ipflufenoquin, iprovalicarb, iptriazopyrid, isocycloseram, isofenphos, isofetamid, isoflualanam, isoflucypram, isoprocarb, isopyrazam, isotianil, isoxachlortole, isoxadifen, isoxaflutole, isoxathion, kadethrin, kappa-bifenthrin, kappa-tefluthrin, karetazan, kinoprene, kresoxim-methyl, lambda-cyhalothrin, lancotrione, ledprona, lepimectin, lufenuron, malathion, mancozeb, mandestrobin, mandipropamid, MCPA, mecarbam, mefenoxam, mefenpyr, mefentrifluconazole, meperfluthrin, mepronil, meptyldinocap, mesosulfuron, mesotrione, metaflumizone, metalaxyl, metalaxyl-M, metamifop, metarylpicoxamid, metazosulfuron, metcamifen, metconazole, methamidophos, methenamine, methidathion, methiocarb, methiozolin (cancelled), methomyl, methoprene, methoxychlor, methoxyfenozide, methylneodecanamide, metobenzuron, metofluthrin, metolcarb, metominostrobin, metosulam, metproxybicyclone, metrafenone, metsulfuron, metyltetraprole, mevinphos, milbemectin, mivorilaner, modoflaner, momfluorothrin, monocrotophos, myclobutanil, naled, napropamide-M, nicobifen, nicofluprole, nicosulfuron, nitenpyram, nithiazine, nitrapyrin, novaluron, noviflumuron, omethoate, orthosulfamuron, orysastrobin, oxadiargyl, oxamyl, oxasulfuron, oxathiapiprolin, oxaziclomefone, oxazosulfyl, oxpoconazole, oxydemeton-methyl, parathion, parathion-methyl, penflufen, penoxsulam, penthiopyrad, pentoxazone, permethrin, pethoxamid, phenothrin, phenthoate, phorate, phosalone, phosmet, phosphamidon, phosphocarb, phoxim, picarbutrazox, picloram, picolinafen, picoxystrobin, pinoxaden, pioxaniliprole, piperflanilide, pirimicarb, pirimiphos-methyl, polyoxorim, prallethrin, profenofos, profluazol, profluthrin, profoxydim, prohydrojasmon, pronitridine, propargite, propetamphos, propiconazole, propoxur, propoxycarbazone, propyrisulfuron, propyzamide, proquinazid, prosulfuron, prothioconazole, prothiofos, protrifenbute, pydiflumetofen,pyflubumide, pymetrozine, pyraclofos, pyraclonil, pyraclostrobin, pyraflufen, pyrafluprole, pyrametostrobin, pyraoxystrobin, pyrapropoyne, pyraquinate, pyrasulfotole, pyraziflumid, pyrethrum, pyribencarb, pyribenzoxim, pyridaben, pyridachlometyl, pyridafol, pyridalyl, pyridaphenthion, pyriflubenzoxim, pyrifluquinazon, pyriftalid, pyrimethanil, pyrimidifen, pyriminobac, pyriminostrobin, pyrimisulfan, pyriofenone, pyriprole, pyriproxyfen, pyrisoxazole, pyrithiobac, pyroxasulfone, pyroxsulam, quinalphos, quinofumelin, quinoxyfen, quizalofop-P, rescalure, resmethrin, rimisoxafen, rimsulfuron, rotenone, saflufenacil, seboctylamine, sedaxane, silafluofen, silthiofam, simeconazole, sintofen, S-metolachlor, spidoxamat, spiflumetofen, spinetoram, spinosad, spirobudifen, spirodiclofen, spiromesifen, spiropidion, spirotetramat, spiroxamine, sulcotrione, sulfentrazone, sulfiflumin, sulfluramid, sulfosulfuron, sulfotep, sulfoxaflor, tau-fluvalinate, tebuconazole, tebufenozide, tebufenpyrad, tebufloquin, tebupirimfos, teflubenzuron, tefluthrin, tefuryltrione, tembotrione, temephos, tepraloxydim, terbufos, tetflupyrolimet, tetrachlorantraniliprole, tetrachlorvinphos, tetradifon, tetramethrin, tetramethylfluthrin, tetraniliprole, thenylchlor, theta-cypermethrin, thiabendazole, thiacloprid, thiamethoxam, thiazopyr, thidiazimin, thiencarbazone, thifluzamide, thiocyclam, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-sodium, thiram, tiadinil, tiafenacil, tigolaner, tiorantraniliprole, tioxazafen, tolfenpyrad, tolprocarb, tolpyralate, topramezone, tralkoxydim, tralomethrin, tralopyril, transfluthrin, triafamone, triazamate, triaziflam, triazophos, tribufos, trichlorfon, triclopyr, triclopyricarb, trifloxystrobin, trifloxysulfuron, trifludimoxazin, trifluenfuronate, triflumezopyrim, triflumuron, triflusulfuron, trimethacarb, trinexapac, tripyrasulfone, triticonazole, tritosulfuron, tyclopyrazoflor, umifoxolaner, uniconazole-P, valifenalate, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, and zoxamide.

2. The composition of claim 1 wherein the compound is selected from the group consisting of Si ,,N N N ,O ,,,,nda m xture partner se ected rom t e group cons st ng o , - , abamectn, acep ate, acequ nocyl, acetamiprid, acetoprole, acibenzolar, acrinathrin, acynonapyr, afidopyropen, alanycarb, aldicarb, aldimorph, allethrin, alpha-bromadiolone, alpha-cypermethrin, alpha-endosulfan, ametoctradin, amicarbazone, amidoflumet, amidosulfuron, aminocyclopyrachlor, aminopyralid, aminopyrifen, amisulbrom, amitraz, anisiflupurin, aviglycine, azadirachtin, azafenidin, azamethiphos, azimsulfuron, azinphos-ethyl, azinphos-methyl, azocyclotin, azoxystrobin, beflubutamid, beflubutamid-M, benalaxyl-M, bencarbazone, benclothiaz, bendiocarb, benfuracarb, benquitrione, bensultap, benthiavalicarb, benzfendizone, benzobicyclon, benzovindiflupyr,benzoximate, benzpyrimoxan, beta-cyfluthrin, beta-cypermethrin, bethoxazin, bicyclopyrone, bifenazate, bifenthrin, bioallethrin, bioresmethrin, bipyrazone, bispyribac, bistrifluron, bisulflufen, bixafen, bixlozone, boscalid, broclozone, broflanilide, bromopropylate, bromuconazole, buprofezin, butafenacil, butocarboxim, butoxycarboxim, butroxydim, cadusafos, cafenstrole, carbaryl, carbofuran, carbosulfan, carboxin, carfentrazone, carpropamid, cartap hydrochloride, carvone, chinomethionat, chlorantraniliprole, chlordane, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroinconazide, chloroprallethrin, chlorpyrifos, chlorpyrifos-methyl, cholecalciferol, chromafenozide, cinidon- ethyl, clacyfos, clethodim, clodinafop, clofencet, clofentezine, clopyralid, cloquintocet, cloransulam, clothianidin, copper hydroxide, coumaphos, coumoxystrobin, cumyluron, cyanophos, cyantraniliprole, cyazofamid, cybutryne, cyclanilide, cyclaniliprole, cyclobutrifluram, cycloprothrin, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxaprid, cyenopyrafen, cyetpyrafen, cyflufenamid, cyflumetofen, cyfluthrin, cyhalodiamide, cyhalofop, cyhalothrin, cyhexatin, cymoxanil, cypermethrin, cyphenothrin, cyprodinil, cyproflanilide, cyprosulfamide, cypyrafluone, cyromazine, d-cis-trans allethrin, DDVP, debacarb, deltamethrin, demeton-S-methyl, diafenthiuron, diazinon, dichlobentiazox, dichlorprop-P, dichlorvos, diclocymet, dicloromezotiaz, diclosulam, dicofol, dicrotophos, dicyclanil, dicyclonon, difenoconazole, diflovidazin, diflubenzuron, diflufenzopyr, diflumetorim, dimefluthrin, dimepropyridaz, dimesulfazet, dimethenamid, dimethenamid-P, dimethoate, dimethylvinphos, dimoxystrobin, dimpropyridaz, diniconazole-M, dinotefuran, diofenolan, dioxopyritrione, dipymetitrone, disulfoton, DNOC, d-trans allethrin, emamectin, emamectin benzoate, empenthrin, endosulfan, enoxastrobin, EPN, epocholeone, epoxiconazole, epsilon-metofluthrin, epsilon-momfluorothrin, epyrifenacil, ergocalciferol, esfenvalerate, ethaboxam, ethametsulfuron, ethiofencarb, ethion, ethiprole, ethoprophos, ethoxysulfuron, etobenzanid, etofenprox, etoxazole, famoxadone, famphur, fenamidone, fenaminstrobin, fenamiphos, fenazaquin, fenbuconazole, fenbutatin oxide, fenhexamid, fenitrothion, fenmezoditiaz, fenobucarb, fenoxanil, fenoxasulfone, fenoxycarb, fenpicoxamid, fenpropathrin, fenpyrazamine, fenpyrazone, fenpyroximate, fenquinotrione, fenthion, fentrazamide, fenvalerate, feproxydim, fipronil, flazasulfuron, flometoquin, flonicamid, florasulam, florpyrauxifen, florylpicoxamid, fluacrypyrim, fluazaindolizine, fluazolate, fluazuron, flubendiamide, flubeneteram, flucarbazone, flucetosulfuron, fluchloraminopyr, fluchlordiniliprole, flucycloxuron, flucythrinate, fludioxonil,fluensulfone, flufenacet, flufenerim, flufenoxadiazam, flufenoximacil, flufenoxuron, flufenoxystrobin, flufenprox, flufenpyr, flufiprole, fluhexafon, fluindapyr, flumethrin, flumetover, flumetsulam, flumetylsulforim, flumiclorac, flumioxazin, flumipropyn, flumorph, fluopicolide, fluopimomide, fluopyram, fluoxapiprolin, fluoxastrobin, fluoxytioconazole, flupentiofenox, flupoxam, flupropacil, flupyradifurone, flupyrimin, flupyroxystrobin, flupyrsulfuron, fluquinconazole, fluroxypyr, flusulfinam, fluthiacet, flutianil, fluxametamide, fluxapyroxad, foramsulfuron, formetanate, fosthiazate, furametpyr, furathiocarb, furilazole, gamma-cyhalothrin, glufosinate-P, glyphosate, halauxifen, halfenprox, halofenozide, halosulfuron, heptafluthrin, heptenophos, hexaflumuron, hexythiazox, hydramethylnon, hydroprene, icafolin, imazamox, imazapic, imazapyr, imazosulfuron, imicyafos, imidacloprid, imiprothrin, indanofan, indazapyroxamet, indaziflam, indolauxipyr, indoxacarb, inpyrfluxam, iodosulfuron, iofensulfuron, ipconazole, ipfencarbazone, ipfentrifluconazole, ipflufenoquin, iprovalicarb, iptriazopyrid, isocycloseram, isofenphos, isofetamid, isoflualanam, isoflucypram, isoprocarb, isopyrazam, isotianil, isoxachlortole, isoxadifen, isoxaflutole, isoxathion, kadethrin, kappa-bifenthrin, kappa-tefluthrin, karetazan, kinoprene, kresoxim-methyl, lambda-cyhalothrin, lancotrione, ledprona, lepimectin, lufenuron, malathion, mancozeb, mandestrobin, mandipropamid, MCPA, mecarbam, mefenoxam, mefenpyr, mefentrifluconazole, meperfluthrin, mepronil, meptyldinocap, mesosulfuron, mesotrione, metaflumizone, metalaxyl, metalaxyl-M, metamifop, metarylpicoxamid, metazosulfuron, metcamifen, metconazole, methamidophos, methenamine, methidathion, methiocarb, methiozolin (cancelled), methomyl, methoprene, methoxychlor, methoxyfenozide, methylneodecanamide, metobenzuron, metofluthrin, metolcarb, metominostrobin, metosulam, metproxybicyclone, metrafenone, metsulfuron, metyltetraprole, mevinphos, milbemectin, mivorilaner, modoflaner, momfluorothrin, monocrotophos, myclobutanil, naled, napropamide-M, nicobifen, nicofluprole, nicosulfuron, nitenpyram, nithiazine, nitrapyrin, novaluron, noviflumuron, omethoate, orthosulfamuron, orysastrobin, oxadiargyl, oxamyl, oxasulfuron, oxathiapiprolin, oxaziclomefone, oxazosulfyl, oxpoconazole, oxydemeton-methyl, parathion, parathion-methyl, penflufen, penoxsulam, penthiopyrad, pentoxazone, permethrin, pethoxamid, phenothrin, phenthoate, phorate, phosalone, phosmet, phosphamidon, phosphocarb, phoxim, picarbutrazox, picloram, picolinafen, picoxystrobin, pinoxaden, pioxaniliprole, piperflanilide, pirimicarb, pirimiphos-methyl, polyoxorim, prallethrin, profenofos, profluazol, profluthrin, profoxydim, prohydrojasmon, pronitridine, propargite,propetamphos, propiconazole, propoxur, propoxycarbazone, propyrisulfuron, propyzamide, proquinazid, prosulfuron, prothioconazole, prothiofos, protrifenbute, pydiflumetofen, pyflubumide, pymetrozine, pyraclofos, pyraclonil, pyraclostrobin, pyraflufen, pyrafluprole, pyrametostrobin, pyraoxystrobin, pyrapropoyne, pyraquinate, pyrasulfotole, pyraziflumid, pyrethrum, pyribencarb, pyribenzoxim, pyridaben, pyridachlometyl, pyridafol, pyridalyl, pyridaphenthion, pyriflubenzoxim, pyrifluquinazon, pyriftalid, pyrimethanil, pyrimidifen, pyriminobac, pyriminostrobin, pyrimisulfan, pyriofenone, pyriprole, pyriproxyfen, pyrisoxazole, pyrithiobac, pyroxasulfone, pyroxsulam, quinalphos, quinofumelin, quinoxyfen, quizalofop-P, rescalure, resmethrin, rimisoxafen, rimsulfuron, rotenone, saflufenacil, seboctylamine, sedaxane, silafluofen, silthiofam, simeconazole, sintofen, S-metolachlor, spidoxamat, spiflumetofen, spinetoram, spinosad, spirobudifen, spirodiclofen, spiromesifen, spiropidion, spirotetramat, spiroxamine, sulcotrione, sulfentrazone, sulfiflumin, sulfluramid, sulfosulfuron, sulfotep, sulfoxaflor, tau-fluvalinate, tebuconazole, tebufenozide, tebufenpyrad, tebufloquin, tebupirimfos, teflubenzuron, tefluthrin, tefuryltrione, tembotrione, temephos, tepraloxydim, terbufos, tetflupyrolimet, tetrachlorantraniliprole, tetrachlorvinphos, tetradifon, tetramethrin, tetramethylfluthrin, tetraniliprole, thenylchlor, theta-cypermethrin, thiabendazole, thiacloprid, thiamethoxam, thiazopyr, thidiazimin, thiencarbazone, thifluzamide, thiocyclam, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-sodium, thiram, tiadinil, tiafenacil, tigolaner, tiorantraniliprole, tioxazafen, tolfenpyrad, tolprocarb, tolpyralate, topramezone, tralkoxydim, tralomethrin, tralopyril, transfluthrin, triafamone, triazamate, triaziflam, triazophos, tribufos, trichlorfon, triclopyr, triclopyricarb, trifloxystrobin, trifloxysulfuron, trifludimoxazin, trifluenfuronate, triflumezopyrim, triflumuron, triflusulfuron, trimethacarb, trinexapac, tripyrasulfone, triticonazole, tritosulfuron, tyclopyrazoflor, umifoxolaner, uniconazole-P, valifenalate, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, and zoxamide.

3. The composition of claim 1, wherein the compound is selected from the group consisting of OOa mixture partner selected from the group consisting of 2,4-D, abamectin, acephate, acequinocyl, acetamiprid, acetoprole, acibenzolar, acrinathrin, acynonapyr, afidopyropen, alanycarb, aldicarb, aldimorph, allethrin, alpha-bromadiolone, alpha-cypermethrin, alpha-endosulfan, ametoctradin, amicarbazone, amidoflumet, amidosulfuron, aminocyclopyrachlor, aminopyralid, aminopyrifen, amisulbrom, amitraz, anisiflupurin, aviglycine, azadirachtin, azafenidin, azamethiphos, azimsulfuron, azinphos-ethyl, azinphos-methyl, azocyclotin, azoxystrobin, beflubutamid, beflubutamid-M, benalaxyl-M, bencarbazone, benclothiaz, bendiocarb, benfuracarb, benquitrione, bensultap, benthiavalicarb, benzfendizone, benzobicyclon, benzovindiflupyr, benzoximate, benzpyrimoxan, beta-cyfluthrin, beta-cypermethrin, bethoxazin, bicyclopyrone, bifenazate, bifenthrin, bioallethrin, bioresmethrin, bipyrazone, bispyribac, bistrifluron, bisulflufen, bixafen, bixlozone, boscalid, broclozone, broflanilide, bromopropylate, bromuconazole, buprofezin, butafenacil, butocarboxim, butoxycarboxim, butroxydim, cadusafos, cafenstrole, carbaryl, carbofuran, carbosulfan, carboxin, carfentrazone, carpropamid, cartap hydrochloride, carvone, chinomethionat, chlorantraniliprole, chlordane, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroinconazide, chloroprallethrin, chlorpyrifos, chlorpyrifos-methyl, cholecalciferol, chromafenozide, cinidon- ethyl, clacyfos, clethodim, clodinafop, clofencet, clofentezine, clopyralid, cloquintocet, cloransulam, clothianidin, copper hydroxide, coumaphos, coumoxystrobin, cumyluron, cyanophos, cyantraniliprole, cyazofamid, cybutryne, cyclanilide, cyclaniliprole, cyclobutrifluram, cycloprothrin, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxaprid, cyenopyrafen, cyetpyrafen, cyflufenamid, cyflumetofen, cyfluthrin, cyhalodiamide, cyhalofop, cyhalothrin, cyhexatin, cymoxanil, cypermethrin, cyphenothrin, cyprodinil, cyproflanilide, cyprosulfamide, cypyrafluone, cyromazine, d-cis-trans allethrin, DDVP, debacarb, deltamethrin, demeton-S-methyl, diafenthiuron, diazinon, dichlobentiazox, dichlorprop-P, dichlorvos, diclocymet, dicloromezotiaz, diclosulam, dicofol, dicrotophos, dicyclanil, dicyclonon, difenoconazole, diflovidazin, diflubenzuron, diflufenzopyr, diflumetorim, dimefluthrin, dimepropyridaz, dimesulfazet, dimethenamid, dimethenamid-P, dimethoate, dimethylvinphos, dimoxystrobin, dimpropyridaz, diniconazole-M, dinotefuran, diofenolan, dioxopyritrione, dipymetitrone, disulfoton, DNOC, d-trans allethrin, emamectin, emamectin benzoate, empenthrin, endosulfan, enoxastrobin, EPN, epocholeone, epoxiconazole, epsilon-metofluthrin, epsilon-momfluorothrin, epyrifenacil, ergocalciferol, esfenvalerate, ethaboxam, ethametsulfuron,ethiofencarb, ethion, ethiprole, ethoprophos, ethoxysulfuron, etobenzanid, etofenprox, etoxazole, famoxadone, famphur, fenamidone, fenaminstrobin, fenamiphos, fenazaquin, fenbuconazole, fenbutatin oxide, fenhexamid, fenitrothion, fenmezoditiaz, fenobucarb, fenoxanil, fenoxasulfone, fenoxycarb, fenpicoxamid, fenpropathrin, fenpyrazamine, fenpyrazone, fenpyroximate, fenquinotrione, fenthion, fentrazamide, fenvalerate, feproxydim, fipronil, flazasulfuron, flometoquin, flonicamid, florasulam, florpyrauxifen, florylpicoxamid, fluacrypyrim, fluazaindolizine, fluazolate, fluazuron, flubendiamide, flubeneteram, flucarbazone, flucetosulfuron, fluchloraminopyr, fluchlordiniliprole, flucycloxuron, flucythrinate, fludioxonil, fluensulfone, flufenacet, flufenerim, flufenoxadiazam, flufenoximacil, flufenoxuron, flufenoxystrobin, flufenprox, flufenpyr, flufiprole, fluhexafon, fluindapyr, flumethrin, flumetover, flumetsulam, flumetylsulforim, flumiclorac, flumioxazin, flumipropyn, flumorph, fluopicolide, fluopimomide, fluopyram, fluoxapiprolin, fluoxastrobin, fluoxytioconazole, flupentiofenox, flupoxam, flupropacil, flupyradifurone, flupyrimin, flupyroxystrobin, flupyrsulfuron, fluquinconazole, fluroxypyr, flusulfinam, fluthiacet, flutianil, fluxametamide, fluxapyroxad, foramsulfuron, formetanate, fosthiazate, furametpyr, furathiocarb, furilazole, gamma-cyhalothrin, glufosinate-P, glyphosate, halauxifen, halfenprox, halofenozide, halosulfuron, heptafluthrin, heptenophos, hexaflumuron, hexythiazox, hydramethylnon, hydroprene, icafolin, imazamox, imazapic, imazapyr, imazosulfuron, imicyafos, imidacloprid, imiprothrin, indanofan, indazapyroxamet, indaziflam, indolauxipyr, indoxacarb, inpyrfluxam, iodosulfuron, iofensulfuron, ipconazole, ipfencarbazone, ipfentrifluconazole, ipflufenoquin, iprovalicarb, iptriazopyrid, isocycloseram, isofenphos, isofetamid, isoflualanam, isoflucypram, isoprocarb, isopyrazam, isotianil, isoxachlortole, isoxadifen, isoxaflutole, isoxathion, kadethrin, kappa-bifenthrin, kappa-tefluthrin, karetazan, kinoprene, kresoxim-methyl, lambda-cyhalothrin, lancotrione, ledprona, lepimectin, lufenuron, malathion, mancozeb, mandestrobin, mandipropamid, MCPA, mecarbam, mefenoxam, mefenpyr, mefentrifluconazole, meperfluthrin, mepronil, meptyldinocap, mesosulfuron, mesotrione, metaflumizone, metalaxyl, metalaxyl-M, metamifop, metarylpicoxamid, metazosulfuron, metcamifen, metconazole, methamidophos, methenamine, methidathion, methiocarb, methiozolin (cancelled), methomyl, methoprene, methoxychlor, methoxyfenozide, methylneodecanamide, metobenzuron, metofluthrin, metolcarb, metominostrobin, metosulam, metproxybicyclone, metrafenone, metsulfuron, metyltetraprole, mevinphos, milbemectin, mivorilaner, modoflaner, momfluorothrin, monocrotophos,myclobutanil, naled, napropamide-M, nicobifen, nicofluprole, nicosulfuron, nitenpyram, nithiazine, nitrapyrin, novaluron, noviflumuron, omethoate, orthosulfamuron, orysastrobin, oxadiargyl, oxamyl, oxasulfuron, oxathiapiprolin, oxaziclomefone, oxazosulfyl, oxpoconazole, oxydemeton-methyl, parathion, parathion-methyl, penflufen, penoxsulam, penthiopyrad, pentoxazone, permethrin, pethoxamid, phenothrin, phenthoate, phorate, phosalone, phosmet, phosphamidon, phosphocarb, phoxim, picarbutrazox, picloram, picolinafen, picoxystrobin, pinoxaden, pioxaniliprole, piperflanilide, pirimicarb, pirimiphos-methyl, polyoxorim, prallethrin, profenofos, profluazol, profluthrin, profoxydim, prohydrojasmon, pronitridine, propargite, propetamphos, propiconazole, propoxur, propoxycarbazone, propyrisulfuron, propyzamide, proquinazid, prosulfuron, prothioconazole, prothiofos, protrifenbute, pydiflumetofen, pyflubumide, pymetrozine, pyraclofos, pyraclonil, pyraclostrobin, pyraflufen, pyrafluprole, pyrametostrobin, pyraoxystrobin, pyrapropoyne, pyraquinate, pyrasulfotole, pyraziflumid, pyrethrum, pyribencarb, pyribenzoxim, pyridaben, pyridachlometyl, pyridafol, pyridalyl, pyridaphenthion, pyriflubenzoxim, pyrifluquinazon, pyriftalid, pyrimethanil, pyrimidifen, pyriminobac, pyriminostrobin, pyrimisulfan, pyriofenone, pyriprole, pyriproxyfen, pyrisoxazole, pyrithiobac, pyroxasulfone, pyroxsulam, quinalphos, quinofumelin, quinoxyfen, quizalofop-P, rescalure, resmethrin, rimisoxafen, rimsulfuron, rotenone, saflufenacil, seboctylamine, sedaxane, silafluofen, silthiofam, simeconazole, sintofen, S-metolachlor, spidoxamat, spiflumetofen, spinetoram, spinosad, spirobudifen, spirodiclofen, spiromesifen, spiropidion, spirotetramat, spiroxamine, sulcotrione, sulfentrazone, sulfiflumin, sulfluramid, sulfosulfuron, sulfotep, sulfoxaflor, tau-fluvalinate, tebuconazole, tebufenozide, tebufenpyrad, tebufloquin, tebupirimfos, teflubenzuron, tefluthrin, tefuryltrione, tembotrione, temephos, tepraloxydim, terbufos, tetflupyrolimet, tetrachlorantraniliprole, tetrachlorvinphos, tetradifon, tetramethrin, tetramethylfluthrin, tetraniliprole, thenylchlor, theta-cypermethrin, thiabendazole, thiacloprid, thiamethoxam, thiazopyr, thidiazimin, thiencarbazone, thifluzamide, thiocyclam, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-sodium, thiram, tiadinil, tiafenacil, tigolaner, tiorantraniliprole, tioxazafen, tolfenpyrad, tolprocarb, tolpyralate, topramezone, tralkoxydim, tralomethrin, tralopyril, transfluthrin, triafamone, triazamate, triaziflam, triazophos, tribufos, trichlorfon, triclopyr, triclopyricarb, trifloxystrobin, trifloxysulfuron, trifludimoxazin, trifluenfuronate, triflumezopyrim, triflumuron, triflusulfuron, trimethacarb, trinexapac,tripyrasulfone, triticonazole, tritosulfuron, tyclopyrazoflor, umifoxolaner, uniconazole-P, valifenalate, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, and zoxamide.

4. The composition of claims 1 to 3 further comprising a source of ammonia.

5. The composition of claims 1 to 4, wherein the source of ammonia is selected from the group consisting of anhydrous ammonia, ammonium nitrate, ammonium sulfate, urea ammonium nitrate, urea, manure, and mixtures thereof.

6. The composition of claims 1 to 5 further comprising a second nitrification inhibiting compound of claim 1.

7. A method of reducing nitrification in soil comprising applying a composition of claims 1 to 6 to soil.

8. The method of claim 7, wherein the composition and source of ammonia are applied simultaneously.

9. The method of claim 7, wherein the composition and source of ammonia are applied sequentially. S TMS 10. A composition and a source of ammonia selected from the group consisting ofnitrate, ammonium sulfate, urea ammonium nitrate, urea, manure, and mixtures thereof.

11. A composition of claim 10 further comprising a mixture partner selected from the group consisting of 2,4-D, abamectin, acephate, acequinocyl, acetamiprid, acetoprole, acibenzolar, acrinathrin, acynonapyr, afidopyropen, alanycarb, aldicarb, aldimorph, allethrin, alpha- bromadiolone, alpha-cypermethrin, alpha-endosulfan, ametoctradin, amicarbazone, amidoflumet, amidosulfuron, aminocyclopyrachlor, aminopyralid, aminopyrifen, amisulbrom, amitraz, anisiflupurin, aviglycine, azadirachtin, azafenidin, azamethiphos, azimsulfuron, azinphos-ethyl, azinphos-methyl, azocyclotin, azoxystrobin, beflubutamid, beflubutamid-M, benalaxyl-M, bencarbazone, benclothiaz, bendiocarb, benfuracarb, benquitrione, bensultap, benthiavalicarb, benzfendizone, benzobicyclon, benzovindiflupyr, benzoximate, benzpyrimoxan, beta-cyfluthrin, beta-cypermethrin, bethoxazin, bicyclopyrone, bifenazate, bifenthrin, bioallethrin, bioresmethrin,bipyrazone, bispyribac, bistrifluron, bisulflufen, bixafen, bixlozone, boscalid, broclozone, broflanilide, bromopropylate, bromuconazole, buprofezin, butafenacil, butocarboxim, butoxycarboxim, butroxydim, cadusafos, cafenstrole, carbaryl, carbofuran, carbosulfan, carboxin, carfentrazone, carpropamid, cartap hydrochloride, carvone, chinomethionat, chlorantraniliprole, chlordane, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroinconazide, chloroprallethrin, chlorpyrifos, chlorpyrifos-methyl, cholecalciferol, chromafenozide, cinidon-ethyl, clacyfos, clethodim, clodinafop, clofencet, clofentezine, clopyralid, cloquintocet, cloransulam, clothianidin, copper hydroxide, coumaphos, coumoxystrobin, cumyluron, cyanophos, cyantraniliprole, cyazofamid, cybutryne, cyclanilide, cyclaniliprole, cyclobutrifluram, cycloprothrin, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxaprid, cyenopyrafen, cyetpyrafen, cyflufenamid, cyflumetofen, cyfluthrin, cyhalodiamide, cyhalofop, cyhalothrin, cyhexatin, cymoxanil, cypermethrin, cyphenothrin, cyprodinil, cyproflanilide, cyprosulfamide, cypyrafluone, cyromazine, d-cis-trans allethrin, DDVP, debacarb, deltamethrin, demeton-S-methyl, diafenthiuron, diazinon, dichlobentiazox, dichlorprop-P, dichlorvos, diclocymet, dicloromezotiaz, diclosulam, dicofol, dicrotophos, dicyclanil, dicyclonon, difenoconazole, diflovidazin, diflubenzuron, diflufenzopyr, diflumetorim, dimefluthrin, dimepropyridaz, dimesulfazet, dimethenamid, dimethenamid-P, dimethoate, dimethylvinphos, dimoxystrobin, dimpropyridaz, diniconazole-M, dinotefuran, diofenolan, dioxopyritrione, dipymetitrone, disulfoton, DNOC, d-trans allethrin, emamectin, emamectin benzoate, empenthrin, endosulfan, enoxastrobin, EPN, epocholeone, epoxiconazole, epsilon- metofluthrin, epsilon-momfluorothrin, epyrifenacil, ergocalciferol, esfenvalerate, ethaboxam, ethametsulfuron, ethiofencarb, ethion, ethiprole, ethoprophos, ethoxysulfuron, etobenzanid, etofenprox, etoxazole, famoxadone, famphur, fenamidone, fenaminstrobin, fenamiphos, fenazaquin, fenbuconazole, fenbutatin oxide, fenhexamid, fenitrothion, fenmezoditiaz, fenobucarb, fenoxanil, fenoxasulfone, fenoxycarb, fenpicoxamid, fenpropathrin, fenpyrazamine, fenpyrazone, fenpyroximate, fenquinotrione, fenthion, fentrazamide, fenvalerate, feproxydim, fipronil, flazasulfuron, flometoquin, flonicamid, florasulam, florpyrauxifen, florylpicoxamid, fluacrypyrim, fluazaindolizine, fluazolate, fluazuron, flubendiamide, flubeneteram, flucarbazone, flucetosulfuron, fluchloraminopyr, fluchlordiniliprole, flucycloxuron, flucythrinate, fludioxonil, fluensulfone, flufenacet, flufenerim, flufenoxadiazam, flufenoximacil, flufenoxuron, flufenoxystrobin, flufenprox, flufenpyr, flufiprole, fluhexafon, fluindapyr, flumethrin,flumetover, flumetsulam, flumetylsulforim, flumiclorac, flumioxazin, flumipropyn, flumorph, fluopicolide, fluopimomide, fluopyram, fluoxapiprolin, fluoxastrobin, fluoxytioconazole, flupentiofenox, flupoxam, flupropacil, flupyradifurone, flupyrimin, flupyroxystrobin, flupyrsulfuron, fluquinconazole, fluroxypyr, flusulfinam, fluthiacet, flutianil, fluxametamide, fluxapyroxad, foramsulfuron, formetanate, fosthiazate, furametpyr, furathiocarb, furilazole, gamma-cyhalothrin, glufosinate-P, glyphosate, halauxifen, halfenprox, halofenozide, halosulfuron, heptafluthrin, heptenophos, hexaflumuron, hexythiazox, hydramethylnon, hydroprene, icafolin, imazamox, imazapic, imazapyr, imazosulfuron, imicyafos, imidacloprid, imiprothrin, indanofan, indazapyroxamet, indaziflam, indolauxipyr, indoxacarb, inpyrfluxam, iodosulfuron, iofensulfuron, ipconazole, ipfencarbazone, ipfentrifluconazole, ipflufenoquin, iprovalicarb, iptriazopyrid, isocycloseram, isofenphos, isofetamid, isoflualanam, isoflucypram, isoprocarb, isopyrazam, isotianil, isoxachlortole, isoxadifen, isoxaflutole, isoxathion, kadethrin, kappa-bifenthrin, kappa-tefluthrin, karetazan, kinoprene, kresoxim-methyl, lambda-cyhalothrin, lancotrione, ledprona, lepimectin, lufenuron, malathion, mancozeb, mandestrobin, mandipropamid, MCPA, mecarbam, mefenoxam, mefenpyr, mefentrifluconazole, meperfluthrin, mepronil, meptyldinocap, mesosulfuron, mesotrione, metaflumizone, metalaxyl, metalaxyl-M, metamifop, metarylpicoxamid, metazosulfuron, metcamifen, metconazole, methamidophos, methenamine, methidathion, methiocarb, methiozolin (cancelled), methomyl, methoprene, methoxychlor, methoxyfenozide, methylneodecanamide, metobenzuron, metofluthrin, metolcarb, metominostrobin, metosulam, metproxybicyclone, metrafenone, metsulfuron, metyltetraprole, mevinphos, milbemectin, mivorilaner, modoflaner, momfluorothrin, monocrotophos, myclobutanil, naled, napropamide-M, nicobifen, nicofluprole, nicosulfuron, nitenpyram, nithiazine, nitrapyrin, novaluron, noviflumuron, omethoate, orthosulfamuron, orysastrobin, oxadiargyl, oxamyl, oxasulfuron, oxathiapiprolin, oxaziclomefone, oxazosulfyl, oxpoconazole, oxydemeton-methyl, parathion, parathion-methyl, penflufen, penoxsulam, penthiopyrad, pentoxazone, permethrin, pethoxamid, phenothrin, phenthoate, phorate, phosalone, phosmet, phosphamidon, phosphocarb, phoxim, picarbutrazox, picloram, picolinafen, picoxystrobin, pinoxaden, pioxaniliprole, piperflanilide, pirimicarb, pirimiphos-methyl, polyoxorim, prallethrin, profenofos, profluazol, profluthrin, profoxydim, prohydrojasmon, pronitridine, propargite, propetamphos, propiconazole, propoxur, propoxycarbazone, propyrisulfuron, propyzamide, proquinazid, prosulfuron, prothioconazole, prothiofos, protrifenbute, pydiflumetofen,pyflubumide, pymetrozine, pyraclofos, pyraclonil, pyraclostrobin, pyraflufen, pyrafluprole, pyrametostrobin, pyraoxystrobin, pyrapropoyne, pyraquinate, pyrasulfotole, pyraziflumid, pyrethrum, pyribencarb, pyribenzoxim, pyridaben, pyridachlometyl, pyridafol, pyridalyl, pyridaphenthion, pyriflubenzoxim, pyrifluquinazon, pyriftalid, pyrimethanil, pyrimidifen, pyriminobac, pyriminostrobin, pyrimisulfan, pyriofenone, pyriprole, pyriproxyfen, pyrisoxazole, pyrithiobac, pyroxasulfone, pyroxsulam, quinalphos, quinofumelin, quinoxyfen, quizalofop-P, rescalure, resmethrin, rimisoxafen, rimsulfuron, rotenone, saflufenacil, seboctylamine, sedaxane, silafluofen, silthiofam, simeconazole, sintofen, S-metolachlor, spidoxamat, spiflumetofen, spinetoram, spinosad, spirobudifen, spirodiclofen, spiromesifen, spiropidion, spirotetramat, spiroxamine, sulcotrione, sulfentrazone, sulfiflumin, sulfluramid, sulfosulfuron, sulfotep, sulfoxaflor, tau-fluvalinate, tebuconazole, tebufenozide, tebufenpyrad, tebufloquin, tebupirimfos, teflubenzuron, tefluthrin, tefuryltrione, tembotrione, temephos, tepraloxydim, terbufos, tetflupyrolimet, tetrachlorantraniliprole, tetrachlorvinphos, tetradifon, tetramethrin, tetramethylfluthrin, tetraniliprole, thenylchlor, theta-cypermethrin, thiabendazole, thiacloprid, thiamethoxam, thiazopyr, thidiazimin, thiencarbazone, thifluzamide, thiocyclam, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-sodium, thiram, tiadinil, tiafenacil, tigolaner, tiorantraniliprole, tioxazafen, tolfenpyrad, tolprocarb, tolpyralate, topramezone, tralkoxydim, tralomethrin, tralopyril, transfluthrin, triafamone, triazamate, triaziflam, triazophos, tribufos, trichlorfon, triclopyr, triclopyricarb, trifloxystrobin, trifloxysulfuron, trifludimoxazin, trifluenfuronate, triflumezopyrim, triflumuron, triflusulfuron, trimethacarb, trinexapac, tripyrasulfone, triticonazole, tritosulfuron, tyclopyrazoflor, umifoxolaner, uniconazole-P, valifenalate, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, and zoxamide.

Images